

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Risk factors for cryptorchidism

### **This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1663083> since 2020-03-31T19:26:25Z

*Published version:*

DOI:10.1038/nrurol.2017.90

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# HHS Public Access

Author manuscript

*Nat Rev Urol.* Author manuscript; available in PMC 2018 February 16.

Published in final edited form as:

*Nat Rev Urol.* 2017 September ; 14(9): 534–548. doi:10.1038/nrurol.2017.90.

## Risk factors for cryptorchidism

Jason K. Gurney<sup>1</sup>, Katherine A. McGlynn<sup>2</sup>, James Stanley<sup>1</sup>, Tony Merriman<sup>3</sup>, Virginia Signal<sup>1</sup>, Caroline Shaw<sup>1</sup>, Richard Edwards<sup>1</sup>, Lorenzo Richiardi<sup>4</sup>, John Hutson<sup>5</sup>, and Diana Sarfati<sup>1</sup>

<sup>1</sup>Department of Public Health, University of Otago, 23a Mein St, Newtown, Wellington 6037, New Zealand <sup>2</sup>Division of Cancer Epidemiology & Genetics, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland 20850, USA <sup>3</sup>Department of Biochemistry, University of Otago, 710 Cumberland Street, North Dunedin, Dunedin 9016, New Zealand <sup>4</sup>Cancer Epidemiology Unit, University of Turin, Via Giuseppe Verdi, 8, 10124 Torino, Italy <sup>5</sup>The Royal Children's Hospital, 50 Flemington Rd, Parkville VIC 3052, Melbourne, Australia

### Abstract

The condition known as **cryptorchidism** – undescended testis – is one of the most common congenital abnormalities found among males, and is one of the few known risk factors for testicular cancer (TC). Like testicular cancer, the key exposures in the occurrence of cryptorchidism remain elusive. Testicular descent is thought to occur during two hormonally-controlled phases – between 8–15 weeks and 25–35 weeks gestation – and while it is clear that a failure of testes to descend permanently is likely due to disruptions to one or both of these phases, the cause(s) and mechanism(s) of such disruption are still unclear. In this manuscript, we review the broad range of putative risk factors that have been evaluated in relation to the development of cryptorchidism to date, discuss their plausibility, and make suggestions regarding further approaches to understand aetiology. There are few exposures for which there is consistent evidence of an association with cryptorchidism; and in those cases where evidence appears unequivocal – for example, the relationship between cryptorchidism and gestational measures such as low birth weight – the measured exposure is likely to be a surrogate for the true causal exposure. The relative importance of each risk factor may vary considerably between mother/son pairs depending on an array of genetic, maternal, placental and foetal factors – all of which could vary between regions.

### Introduction

Descent of the testes into the temperate environment of the scrotum represents a vital developmental step on the path toward successful human reproduction. **Cryptorchidism** – failure of one or both testes to permanently descend, otherwise referred to as undescended testis – is one of the most common congenital abnormalities among males:<sup>1</sup> approximately 1–9% of all males are born with at least one cryptorchid testis.<sup>2–8</sup> While about half of these

cases will spontaneously descend during the first three months of life, approximately 1% of all males will remain cryptorchid at the end of their first year.<sup>3,8,9</sup>

Cryptorchidism is one of the few known risk factors for testicular cancer:<sup>10</sup> men with a history of cryptorchidism have a three-<sup>11</sup> to four-fold <sup>12</sup> increased risk of testicular cancer compared to those with no history of cryptorchidism. It is estimated that 5–9% of all men who develop testicular cancer have a history of persistent cryptorchidism.<sup>13,14</sup>

Cryptorchidism is also a risk factor for sub-fertility: it is estimated that men with a history of cryptorchidism are twice as likely to be sub-fertile compared to those without cryptorchidism.<sup>15</sup> Cryptorchidism is also one component of theorised Testicular Dysgenesis Syndrome, a syndrome in which four individual conditions (cryptorchidism, TC, hypospadias and sub-fertility) possibly share the same prenatal risk factors.<sup>16</sup> Hypospadias – a congenital anomaly where the urethra terminates on the underside of the penis, rather than at the tip of the glans <sup>17</sup> – is relatively more common among those with cryptorchidism; however, in absolute terms only a small proportion of boys born with cryptorchidism will also have hypospadias (approximately 2%).<sup>18</sup> In rare cases, the testis will disappear due to torsion or some other unknown cause – a condition called Testicular Regression Syndrome, also known as ‘vanishing testis’.<sup>19</sup>

The primary treatment for cryptorchidism is the surgical repositioning of the cryptorchid testis into the scrotum, a procedure known as orchidopexy.<sup>20,21</sup> In cryptorchid neonates it is recommended that this procedure be performed within one year of birth, while cases of ‘acquired’ cryptorchidism in early childhood should be treated immediately.<sup>22,23</sup> Performing orchidopexy before puberty reduces the subsequent risk of testicular cancer relative to later correction:<sup>24</sup> for example, cryptorchid boys who undergo orchidopexy after the age of 12 (or not at all) are 2–6 times more likely to have testicular cancer compared to those who receive the corrective treatment before the age of 12.<sup>25</sup>

The relationship between cryptorchidism and testicular cancer remains unclear. In unilateral cryptorchidism, the increased risk of testicular cancer is much weaker in the contralateral than in the ipsilateral testis (relative risk [RR] of testicular cancer in cryptorchid testis: 6.33, 95% CI 4.30–9.31; contralateral testis RR 1.74, 95% CI 1.01–2.98) <sup>26</sup> – suggesting that the link between cryptorchidism and testicular cancer is mostly related to variable manifestation of a shared risk factor, rather than a more generalised developmental abnormality that equally affects both testes.<sup>25,27</sup> A testicular defect acquired in the intrauterine environment may be linked to both the development of cryptorchidism and to the risk of neoplasia within the cryptorchid testes, with a consequent increased risk of testicular cancer in later life.<sup>12,28</sup>

### **Temporal and geographic variation in disease occurrence**

In terms of changes in the occurrence of cryptorchidism over time, we observe conflicting evidence – with some reports of increasing occurrence in recent decades,<sup>7,29,30</sup> and others reporting stable or decreasing occurrence.<sup>2,31–33</sup> This variation in temporal observations – as well as the wide variation in cryptorchidism occurrence as reported in the literature (1–9%) – is at least partially an indication of the wide geographical variation that has been observed between countries. For example, boys born in Denmark are more than four times as likely to have cryptorchidism as boys born in Finland, while boys born in Lithuania have an

intermediate prevalence between Denmark and Finland.<sup>5,7</sup> The reason for this geographic variation remains poorly understood – but at the very least suggests that the factors that predispose an individual to cryptorchidism are unevenly distributed between population groups.

### **Congenital vs. ‘acquired’ cryptorchidism**

For the purposes of this manuscript, we define cryptorchidism as a congenital condition<sup>34,35</sup> – not because of the timing of condition presentation and/or discovery (which can vary), but rather the likely timing of disease aetiology. We acknowledge that there are several variations in terms of the former: a boy may present with/be discovered to have cryptorchidism at or soon after birth (‘congenital’ cryptorchidism, in the traditional sense); a boy may have normally-descended testes at birth, one or both of which subsequently ascend (‘acensus testis’), or a boy may have one or both initially-cryptorchid testes that spontaneously descend and then re-ascend (‘recurrent’ cryptorchidism).<sup>36</sup> However for the purposes of this manuscript we consider the non-permanent descent of testes as being congenital in origin<sup>37</sup> – regardless of when this condition presents.

These variations in condition presentation and/or discovery may have important ramifications for measurement of disease occurrence. Firstly, measurements of disease prevalence at two years of age will exclude boys whose initially-cryptorchid testis have spontaneously descended; likewise, measurements taken at birth will exclude boys with normally-descended testis that subsequently ascend spontaneously. Secondly, cryptorchidism diagnosis can be performed via either clinical examination or be based on receipt of orchidopexy – with orchidopexy-confirmed cryptorchidism more likely to reflect ‘persistent’ cryptorchidism cases than clinically-diagnosed cryptorchidism.<sup>38</sup> Thus, as well as reflecting geographic variance, the wide variation in disease occurrence (1–9%) may also reflect the difficulty in ascribing true disease prevalence when the condition occurs across a severity spectrum.

### **The anatomy of testicular descent**

Comprehensive reviews of the process of testicular descent can be found elsewhere.<sup>18,39</sup> Briefly, the primary factors that drive testicular descent during prenatal/perinatal life are thought to occur during two hormonally-controlled phases – between 8–15 weeks and 25–35 weeks gestation (Figure 1). A failure of one or both testes to descend permanently must be caused by some disruption to these phases. In this manuscript, we review the broad range of putative risk factors hypothesised to be associated with the development of cryptorchidism to date, discuss their plausibility with respect to influence on descent of the testis *in utero*, and make suggestions regarding those risk factors that require further investigation.

### **Hormones**

Since testicular descent is a hormonally-driven event, it is possible that the exposures discussed throughout this review are causes of (or proxies for) some abnormality in intrauterine hormonal function.<sup>40</sup> Several authors have directly measured intrauterine hormone levels and compared these between those mothers of sons who developed

cryptorchidism and those that did not. Based on their role in testicular descent, these investigations have primarily focussed on estrogens, androgens, human chorionic gonadotrophin (hCG) and the protein hormone Insulin-Like 3 (INSL3).

## Estrogen

The estrogen hypothesis proposed by Sharpe and Skakkebaek in 1993<sup>41</sup> suggests foetal exposure to high levels of endogenous estrogen may be associated with maldescent of the testes (among other urogenital conditions). However, there is little<sup>42</sup> or no<sup>43,44,54-48</sup> evidence that this is the case; in fact, two previous studies have observed lower serum estrogen levels among mothers of cryptorchid cases compared to mothers of controls.<sup>43,44</sup> Some authors have observed higher levels of serum alpha-fetoprotein (AFP) – a protein thought to mediate how the developing foetus responds to estrogen – among mothers of cryptorchid boys compared to mothers of non-cryptorchid boys;<sup>43,49</sup> however, other authors have found no such association<sup>50</sup> – and given the lack of evidence regarding the role of maternal estrogen levels, it seems more likely that this difference in AFP levels may reflect some other dysfunction of the placenta.<sup>43,49</sup> The role of the synthetic estrogen *diethylstilbestrol* (DES) is discussed later in this review ('Pregnancy-related medications').

## Testosterone

Testosterone is critical to successful testicular descent: for instance, cryptorchidism can be achieved in animal models by exposing the animal to pure anti-androgens.<sup>51-53</sup> It has therefore been hypothesised that low maternal levels of testosterone might be associated with development of cryptorchidism in the son. However, studies that have directly measured maternal testosterone levels in serum have reported little<sup>45</sup> or no<sup>42,43</sup> evidence of an association with cryptorchidism. Similarly, studies that have measured testosterone levels in cord blood found no evidence of an association between reduced testosterone levels and the development of cryptorchidism.<sup>55,56</sup>

## Human Chorionic Gonadotrophin

Testosterone is produced (and regulated) by the developing testes primarily in response to human chorionic gonadotrophin (hCG), a hormone produced by the placenta.<sup>50,57</sup> Some authors have hypothesised that disruption to hCG production may be associated with maldescent of the developing testes, with Chedane et al.<sup>50</sup> recently showing that the placentas of boys born with cryptorchidism had somewhat lower total hCG levels compared to controls (case mothers: 21.4 kilounits/litre, control mothers: 27.7 kilounits/litre). The authors suggest that the lower hCG values observed in the placentas of boys with cryptorchidism could reflect lower testosterone production, which in turn could lead to deficiencies in testicular descent;<sup>50</sup> however, this relationship remains unclear.

## Insulin-Like 3 (INSL3)

Like testosterone, the protein hormone INSL3 is crucial to testicular descent: cryptorchidism can be achieved in animal models by knocking out the gene that encodes INSL3.<sup>58</sup> In recent years, it has been reported that cord blood levels of INSL3 are lower in children born with cryptorchidism<sup>56,55,59</sup> and might be reduced by exposure to exogenous endocrine-disrupting

chemicals.<sup>56,60</sup> However more direct observation of the pathway between exogenous stimuli (such as chemicals), altered intrauterine INSL3 levels and cryptorchidism development is required in order to substantiate causality. The role of endocrine-disrupting chemicals as a risk factor for cryptorchidism is discussed elsewhere in this review.

## Assisted reproduction

Children conceived by in-vitro fertilisation (IVF) are 30% more likely to have a congenital malformation compared to those conceived naturally; however the absolute risk of malformation remains low.<sup>61</sup> The mechanism of causality – if one exists – is suspected to be multifactorial, and perhaps involves endocrine disruption caused by stimulation of the ovaries in order to produce multiple oocytes, as well as factors directly related to the IVF procedure itself.<sup>62</sup>

However, there is limited <sup>63,64,65,66,67,68,69</sup> or no <sup>70</sup> evidence of an independent association between assisted reproduction procedures (ART) and development of cryptorchidism in the resulting child. In two studies a crude association between conception and cryptorchidism was substantially reduced after adjustment for birthweight. This suggests that the increased propensity for ART children to be born prematurely and with low birthweight <sup>63</sup> – discussed later in this manuscript as risk factors for cryptorchidism – may act as confounders or mediators in the association between ART and cryptorchidism.

Another significant confounding factor – which cannot be easily managed in study design or analysis – is that those seeking such fertility treatment are, by definition, sub-fertile. Subfertility is itself a risk factor for congenital malformation: for example, the children of sub-fertile parents (that is, those who took longer than 12 months to naturally conceive) are 20–40% more likely to have some congenital malformation compared to those who took less than 12 months to conceive.<sup>71</sup> Massaro et al.<sup>72,73</sup> suggest that parental subfertility (regardless of which parent[s] are affected) is likely to make a more substantial contribution to risk of congenital malformation than the means of conception.<sup>72,73</sup> Kallen et al.<sup>74</sup> observed that controlling for characteristics of the parent – including length of ‘involuntary childlessness’ – almost entirely explained the increased risk of congenital abnormality found among those conceived via IVF.<sup>74</sup> In other words, it is possible that the association between ART and cryptorchidism is due to parental and neonatal characteristics that are common to those seeking and receiving this treatment.

## Maternal age, parity and health

### Maternal age

While little difference in mean maternal age has been observed between the mothers of cryptorchid compared to non-cryptorchid sons <sup>75,76,77,78,79,80,81,68,65,46</sup>, some authors have observed an association between both ‘older’ (>30 years) <sup>77,82,83</sup> and ‘younger’ (<20 years) <sup>76,77,84,85</sup> maternal age and cryptorchidism. In contrast to the latter, both Jones et al.<sup>48</sup> and McGlynn et al.<sup>82</sup> observed that young age appeared to be protective against cryptorchidism development. In the absence of consistent observations, it is difficult to draw firm conclusions regarding the role of maternal age in the aetiology of cryptorchidism.

## Parity

Any relationship between parity (and/or birth order) and risk of cryptorchidism is unclear: while several authors have found no association,<sup>7678866575</sup> others have found an increased risk of cryptorchidism among sons born to both primiparous mothers<sup>878889488384</sup> – while still others have found increased risk among sons born to multiparous mothers.<sup>77</sup> It is worth noting that those studies that observed an increased risk of cryptorchidism among sons born to multi-<sup>77</sup> or primiparous mothers<sup>48,83,84,87–89</sup> tended to have larger sample sizes than those that found no association,<sup>5,6,75,76,78,86</sup> and thus had greater power to detect an association, and that among those larger studies there was more consistency towards an increased risk among firstborn men. It has been hypothesized that this association is related to hormonal differences in nulliparous women compared with multiparous women.<sup>17</sup> Women in their first pregnancy have higher levels of free estradiol than in subsequent pregnancies,<sup>28</sup> and

## Pregnancy-related health

A multitude of factors related to the health of the mother have been investigated as potential risk factors for cryptorchidism development, perhaps due to their relevance to pregnancy. However, there is little consistent evidence that these maternal factors are strong risk factors in the development of cryptorchidism – and as such, we have reserved a detailed description of these factors for supplementary material (see Supplementary Material 1).

## Alcohol

When viewed collectively, the literature to date provides little<sup>93</sup> or no<sup>799499966467895769289</sup> evidence that maternal alcohol consumption during pregnancy is associated with cryptorchidism development. A recent meta-analysis reported a null association (adjusted pooled odds ratio: 0.97, 95% CI 0.87–1.07).<sup>100</sup>

However, there is limited evidence that ‘heavy’ drinking (relative to reported abstinence) might be associated with cryptorchidism development: whether via chronic exposure in terms of a relatively large number of drinks per week<sup>9897</sup> or via binge drinking episodes.<sup>979996</sup> For example, Damgaard et al.<sup>97</sup> observed that the sons of mothers who regularly consumed at least 5 drinks per week during pregnancy had three times greater odds of developing cryptorchidism compared to those not exposed (adjusted OR: 3.10, 95% CI 1.05–9.10). However, the authors found no conclusive evidence of an association between binge drinking episodes (i.e. instances where the mother was “noticeably inebriated”) and cryptorchidism development (adjusted OR: 1.18, 95% CI 0.77–1.83), findings which largely echo those observed by Jensen et al.<sup>96</sup> and Strandberg-Larsen et al.<sup>99</sup> It is worth noting that observations regarding the impact of ‘heavy’ drinking have been made based on small proportion of exposed cases – for instance, of the n=2,477 mothers investigated in Damgaard et al.,<sup>97</sup> only 34 consumed at least 5 drinks per week during pregnancy – of which 6 had a son who developed cryptorchidism (out of the total 128 cases) and 28 did not. Strandberg-Larsen et al.<sup>99</sup> had the greatest power to detect an association between ‘heavy’ drinking and cryptorchidism development, with a cohort of more than n=41,000 and n=1,598 cryptorchidism cases; still, they found no such association.

Based on evidence to date, it would appear that alcohol is not a major risk factor in the development of cryptorchidism; however, there are a number of issues with exposure assessment that require further consideration. Firstly there is likely to be social desirability bias when using self-report to measure alcohol consumption during pregnancy.<sup>95</sup> Secondly the aggregation of studies with different exposure assessment of alcohol consumption (e.g. binge vs ever drinking) may mask any true associations. Thirdly, the lack of consistent definitions of the same exposure (e.g. what constitutes binge drinking) also means it is possible that a true association may not be apparent due to poor, and thus misclassified, exposure assessment. Given a possible association between sustained heavy consumption or binge drinking and cryptorchidism development, standardisation of how these exposures are measured is necessary.

## Tobacco

The disruptive impact of tobacco exposure on the intrauterine environment is unequivocal.<sup>101</sup> In addition to the various means by which tobacco exposure might affect testicular maldescent (including cellular genetic mutation and vasoconstriction),<sup>102</sup> it has also been shown that the endocrine system – upon which successful descent of the testes depends – is disrupted by cigarette smoke.<sup>103</sup>

## Maternal smoking during pregnancy

There is some evidence of a weak positive association between maternal smoking during pregnancy and subsequent development of cryptorchidism.<sup>9446589758092824076104105</sup> Two separate meta-analyses have confirmed this association,<sup>100,106</sup> with the most recent including information from 25 studies and observing a 17% increased risk of cryptorchidism among boys born to mothers who smoked tobacco during pregnancy (pooled OR: 1.17, 95% CI: 1.11–1.23).<sup>100</sup> To put this into perspective, the association between maternal smoking and the development of cryptorchidism is comparable to that observed for smoking and cleft lip defect (OR range 1.2–1.6).<sup>101</sup>

Further evidence of an association was provided by Thorup et al.,<sup>107</sup> who observed that among children born with cryptorchidism, chances of bilateral cryptorchidism (maldescent of both testes) is 50% among children born to mothers who smoked at least 10 cigarettes per day during pregnancy, but only 18% among those mothers who did not smoke during pregnancy, adjusted for birth weight.<sup>107</sup>

However, there are some caveats to the evidence around maternal smoking and risk of cryptorchidism. First, there is the issue of study quality: there has been a high degree of both inconsistency and imprecision in the measurement of maternal smoking during pregnancy. Most studies to date have employed an ‘any-use’ means of measuring tobacco exposure, and/or have collected smoking status data at relatively arbitrary times during the antenatal period.<sup>465488910880,9467578408298</sup> This means that most studies ignore plausible dose-response relationships between the number of cigarettes smoked per day and cryptorchidism development, for which there is some evidence: Jensen et al. observed increasing risk of cryptorchidism with increasing numbers of cigarettes smoked per day (albeit with wide confidence intervals).<sup>105</sup> It also means that most studies ignore the possibility that the timing

of tobacco exposure is important (including timing of cessation among those who quit during pregnancy). One conceivable (though probably simplistic) explanation for why several studies have observed a null<sup>66810879</sup> or weak<sup>9446548807892408298</sup> association between maternal smoking and cryptorchidism might be due to poor data quality and/or incomplete analytical accounting for the intensity and timing of smoking. An exception to this is the study by Mongraw-Chaffin et al.,<sup>95</sup> which collected comprehensive prospective data on tobacco exposure during pregnancy and found a null (if not weak negative) result. These data were collected between 1959–1967, well before the 1980 Surgeon General’s Report on the Health Consequences of Smoking for Women<sup>109</sup> – and as such, the prevalence of maternal smoking was high within both case (49%) and control groups (58%).<sup>95</sup> However, it should be noted that the multivariable models run by Mongraw-Chaffin et al.<sup>95</sup> only included data on n=68 cases and n=212 controls – and thus the author’s ability to detect potentially-important associations due to the comprehensive nature of data collection may be diluted by the small size of their sample.

Second, the issue of social desirability bias and possible under-reporting of tobacco use applies here. While recall bias not an issue for those studies which collect tobacco exposure data prospectively,<sup>95</sup> under-reporting is still highly likely regardless of study design and in prospective studies will likely result in the measure of association being biased towards the null.<sup>101</sup> One approach to dealing with error in self-reported smoking status is to use a biologic measurement (e.g. via serum cotinine). This would seem a critical future step in validating the association between maternal smoking and cryptorchidism development.<sup>102</sup>

### Paternal smoking

There appears to be consistent (albeit weak) evidence of an association between paternal smoking and cryptorchidism in the son.<sup>758079105104</sup> For example, Jensen et al.<sup>105</sup> observed that paternal smoking during pregnancy increased the odds of cryptorchidism by 60% (unadjusted OR: 1.6, 95% CI 1.2–2.3).

It is difficult to discern whether the association between paternal smoking and cryptorchidism development is a causal or spurious one. Jensen et al.<sup>105</sup> observed that the relationship between paternal smoking and cryptorchidism development did not disappear when additionally adjusted for maternal smoking; and it is conceivable that paternal smoking is associated with cryptorchidism via passive maternal exposure<sup>10475105</sup> or genetic ‘damage’ to the sperm involved in conception.<sup>79,104</sup> However, it is possible that the association may simply be the result of a strong correlation between maternal smoking (which may be underreported by mothers) and paternal smoking (for whom social desirability bias may have less impact on self-report).<sup>105</sup> As suggested by Jensen et al.,<sup>105</sup> measurement of serum cotinine (or a similar biomarker) would be a useful means of testing the independence of the relationship between paternal and maternal smoking and cryptorchidism development.

### Drugs

Broadly speaking, drugs that have been studied for an association with cryptorchidism can be grouped as a) medications for conditions directly related to the pregnancy and/or fertility,

b) medications for conditions unrelated to the pregnancy (excluding analgesics), c) analgesics, and d) recreational drugs (or non-therapeutic use of medicines).

### Pregnancy-related medications

Multiple studies have investigated the association between medications that may be taken to facilitate (or prevent) pregnancy; prevent pregnancy loss or complication(s); or treat nausea and vomiting. Studies have reported either little or no consistent evidence of an association between cryptorchidism risk and maternal use of anti-nausea/vomiting medications,<sup>76,78</sup> fertility medications<sup>76</sup> or contraceptive medications.<sup>76,78,110</sup> In terms of medications used to prevent pregnancy loss or complications, some authors have found no association;<sup>76,78</sup> however, Palmer et al.<sup>111</sup> observed an association between the synthetic estrogen *diethylstilbestrol* (DES) – widely given to women throughout the mid-20<sup>th</sup> century, ostensibly to prevent pregnancy complications – and development of cryptorchidism in sons (adjusted RR: 1.9, 95% CI 1.1–3.4). It is worth noting that most of these studies had relatively small sample sizes, and thus their power to detect associations was limited; for example, of the n=2,235 mothers investigated in Palmer et al.,<sup>111</sup> only 54 had children who developed cryptorchidism – of which 38 were exposed to DES and 17 were not.<sup>76,78,110,111</sup>

Mavrogenesis et al.<sup>110</sup> also observed an association between *dydrogesterone* treatment (commonly for pre-pregnancy endometriosis) and development of cryptorchidism (adjusted OR: 2.75, 95% CI 1.04–7.28) – although the authors acknowledge the preliminary nature of this observation, since it was based on only 5 (out of 2,052) cases and 22 (out of 24,814) controls.

### Medications for conditions unrelated to the pregnancy (excluding analgesics)

Several studies have investigated medications that may be taken by a mother during pregnancy to treat conditions unrelated to pregnancy – including anti-retrovirals,<sup>112</sup> antibiotics for fungal or bacterial infection,<sup>113,114</sup> anti-depressives,<sup>115</sup> laxatives,<sup>116</sup> cough medications,<sup>117</sup> anti-anaemics<sup>46</sup>, hypnotics,<sup>46</sup> and anti-epileptics.<sup>118,119,120</sup> In the majority of these studies, cryptorchidism was one of many congenital anomalies under investigation, and each study generally included a small number of cryptorchidism cases. These studies have found little or no association between use of these medications and subsequent cryptorchidism risk – with the possible exception of Bartfai et al.,<sup>117</sup> who observed that boys born to mothers who reported using Prenoxdiazine (cough medicine) at some point during pregnancy appeared to be at increased risk of cryptorchidism (adjusted OR: 1.8, 95% CI 0.9–3.5). However, given the small number of cases upon which this association was made (n=21), further research is required to substantiate this observation.

### Analgesics

Perhaps the most investigated group of drugs in the context of congenital cryptorchidism are analgesics, such as paracetamol and ibuprofen. Analgesics have been implicated as endocrine disruptors, and it has been shown that clinically-relevant concentrations can cause endocrine disturbances in the human fetal testis.<sup>121</sup> Several authors have observed a strong positive association between maternal use of analgesics and cryptorchidism in their sons.<sup>94,122–124</sup> For example, Snijder et al.<sup>122</sup> observed that women who used mild analgesics

during their second trimester had more than twice the odds of giving birth to sons who had cryptorchidism (adjusted OR: 2.12, 95% CI 1.17–3.83), and after calculating population-attributable fractions (PAFs) concluded that up to 24% of all cryptorchidism cases in their cohort could be attributed to the maternal use of mild analgesics during pregnancy.

However, there is also conflicting evidence regarding an association between maternal use of analgesics and cryptorchidism, with several authors finding no<sup>6,78</sup> or weak/limited<sup>46,125,126</sup> evidence. We cannot easily attribute this conflict to differing exposure and outcome classification between studies: for example, Kristensen et al.<sup>123</sup> compared the association between maternal use of mild analgesics (including acetaminophen) and development of cryptorchidism in both Denmark and Finland, and observed a dose-dependent positive association in Denmark (e.g. adjusted OR for use of mild analgesics for more than two weeks during first and second trimester: 2.47, 95% CI 1.02–5.96) but not in Finland (same OR: 0.56, 95% CI 0.13–2.45). While some heterogeneity in exposures might be expected between countries and study power the extent of this divergence is difficult to explain – and adds some confusion regarding the possible role of analgesia in the development of cryptorchidism. The authors themselves state that rather than having a directly causal relationship with cryptorchidism development, it is entirely possible that maternal use of analgesics may in fact be a “sentinel” of other (unmeasured) factors.<sup>127</sup> It is also worth noting that, with the possible exception of Jensen et al.,<sup>124</sup> the studies that have investigated analgesia exposure have generally involved a relatively small number of cases – thus limiting the power of these studies to detect an association.

The ubiquity of analgesia use makes this exposure particularly important from a public health perspective – and given this fact, further well-powered, multivariate-adjusted investigations and meta-analyses are required to better assess this exposure.

### Recreational drug use

Very few studies have investigated the association between maternal use of drugs which might be considered ‘recreational’ and the subsequent development of cryptorchidism in the son. Berkowitz and Lapinski<sup>94</sup> observed that maternal ‘drug abuse’ had no effect on cryptorchidism risk. While marijuana use by males has been reported to be associated with testicular cancer,<sup>128–131</sup> there have been no studies to date examining maternal use of marijuana and cryptorchidism.

### Endocrine-disrupting chemicals

A number of chemicals have been identified as potential disruptors of endocrine system function – and numerous animal studies have shown that exposure to these chemicals can interrupt normal testicular descent.<sup>132133134135136137</sup> There is an extensive body of literature examining the impact of these endocrine-disrupting chemicals on the prevalence of cryptorchidism in humans – and it is possible to classify this literature as referring to either occupational or environmental exposure.

## Occupational exposure

Multiple authors have investigated the association between certain occupations and the development of cryptorchidism, with occupation acting as a proxy for exposure(s) that are thought to cause cryptorchidism. With a few rare exceptions, the underlying exposures of interest are synthetically-manufactured chemicals, particularly pesticides used in the agricultural industry. Several studies have observed an increased risk of cryptorchidism arising from maternal agri/horticultural occupation during pregnancy.<sup>98,138–140</sup> For example, Jorgensen et al.<sup>138</sup> observed in a large Danish cohort that sons of mothers who farmed during pregnancy were nearly a third more likely to develop cryptorchidism compared to sons of mothers who did not farm (adjusted HR: 1.31, 95% CI 1.12–1.53). Several authors have also observed an increased risk of cryptorchidism among boys born to fathers who are agri/horticultural workers,<sup>75,98,141</sup> although the mechanism by which paternal exposure affects the developing foetus remains unclear.

Morales-Surez-Varela et al.<sup>142</sup> observed that occupations with increased risk of paternal exposure to heavy metals were associated with an increased risk of cryptorchidism in sons (adjusted HR: 1.9, 95% CI 1.1–2.7); however, maternal exposure during pregnancy was not associated (adjusted HR: 1.0, 95% CI 0.3–1.7).<sup>142</sup> Similarly, Vaktskjold et al.<sup>143</sup> observed no association between pregnant women working in a nickel factory and cryptorchidism (adjusted OR: 0.76, 95% CI 0.40–1.47).

Hairdressing has been investigated by one study as a proxy for solvent exposure, though there is little evidence of an association with cryptorchidism – with Jorgensen et al.<sup>144</sup> observing that boys born to women who worked as hairdressers during pregnancy were no more likely to develop cryptorchidism than sons whose mothers worked in other occupations (adjusted HR: 0.91, 95% CI 0.77–1.08). Finally, there is limited evidence that the sons of soldiers exposed to the endocrine-disrupting chemical *dibutyl phthalate* during the 1940's-1960's were more likely to be born cryptorchid; however this evidence is based on a very small cohort.<sup>145</sup>

## Environmental exposure – indirect measurement

Other studies have investigated the association between environmental exposure to endocrine disrupting chemicals and cryptorchidism. Bornman et al.<sup>146</sup> observed that sons born to women who lived in areas sprayed with *dichlorodiphenyltrichloroethane* (DDT) were more than twice as likely to be born cryptorchid (adjusted OR: 2.1, 95% CI 1.14–3.92).

Several authors have estimated likely pesticide exposure according to the geographic region in which the child was born. This classification has been based on intensity of agricultural industry in the region,<sup>147,148</sup> representative samples taken as part of a geological survey,<sup>149</sup> or proximity to chemical plants.<sup>150,151</sup> With respect to the latter, there is some evidence that proximity to a chemical plant is related to cryptorchidism risk. Czeizel et al.<sup>150</sup> observed in a large Hungarian cohort that the risk of cryptorchidism increased with proximity to the local *acrylonitrile* factory (a chemical used in plastic manufacturing) – while Kim et al.<sup>151</sup> observed that the risk of cryptorchidism was higher in those regions of South Korea that have petrochemical estates, compared to the national average.<sup>151</sup> While offering little insight

into the specific chemical exposures that may be associated with cryptorchidism development, these observations suggest – at least ecologically – that exposure to potentially-endocrine-disrupting chemicals may increase the risk of cryptorchidism development.

### Environmental exposure – direct measurement

Rather than indirectly measure exposure to potential endocrine-disrupting chemicals via a proxy such as geographical location or occupation, a number of researchers have collected biological specimens and directly tested for the presence of these chemicals. The medium for this analysis varies: many studies have used maternal blood taken during pregnancy,<sup>152–158</sup> although neonatal serum,<sup>159,160</sup> amniotic fluid,<sup>60</sup> breast milk,<sup>159,161–166</sup> placental tissue/cord blood<sup>159–162,166–172</sup> and adipose tissue biopsy from the child<sup>173,174</sup> have also been employed. Those studies investigating early-life environmental exposure to endocrine-disrupting chemicals as a risk factor for cryptorchidism have generally drawn blood from the children themselves.<sup>175,176</sup>

Despite extensive evaluation, the role of direct exposure to endocrine-disrupting chemicals remains uncertain. Some authors have observed higher levels of the compounds *bisphenol A*,<sup>176</sup> *dibutyltin*<sup>169</sup> *dioxin*,<sup>164,173</sup> *heptachloroepoxide*,<sup>174</sup> *hexachlorobenzene*,<sup>174</sup> *polychlorinated biphenyls*<sup>164,173,177</sup> and *polybrominateddiphenyl ethers*<sup>159,164</sup> among boys (and/or their mothers) who developed cryptorchidism compared to those who did not; however a substantial number of studies (at least some of which were adequately powered to detect an association) have directly evaluated these and other biologically-plausible compounds and found no such association.<sup>56,60,152–157,160,163,168,172,178</sup> In some cases, studies have found substantial regional heterogeneity, including conflicting results between countries within the same study.<sup>161,162,164,169</sup> For example, Rantakokko et al.<sup>169</sup> observed that maternal exposure to high levels (>0.15ng/g) of *dibutyltin* was associated with increased risk of cryptorchidism in Danish sons (adjusted OR vs. <0.10ng/g: 4.01, 95% CI 1.42–11.33), but was inversely associated in Finnish sons (adjusted OR: 0.16, 95% CI 0.03–0.75).

There is some evidence that rather than an individual chemical type being associated with cryptorchidism development, it is the mixture<sup>167,171</sup> or total burden<sup>165,170,173,177</sup> of chemical exposure that is important. For example, Damgaard et al.<sup>165</sup> observed no (or very limited) association between individual compounds extracted from breast milk and cryptorchidism in the son – however, when the eight most commonly-occurring compounds (*dichlordiphenyldichloroethylene* [DDE], DDT,  $\beta$ -*hexachlorocyclohexane*], *hexachlorobenzene*],  *$\alpha$ -endosulfan*, *cis-heptachloroepoxide*, *oxychlorodane* and *dieldrin*) were combined, the authors observed higher levels of these pesticides among boys with cryptorchidism compared to boys without.

Overall, the evidence regarding the association between cryptorchidism and exposure to potential endocrine-disrupting chemicals suggests a weak and inconsistent association – perhaps stronger in some contexts than others<sup>161,162,164,169</sup> for reasons that are not presently clear. It also remains unclear if the higher levels of compounds observed among cryptorchid boys (or their mothers) in some studies is indicative of heightened exposure to these chemicals, or indicates inability to metabolise those chemicals.<sup>166</sup> We should also note

that exposure to some of these chemicals has been in decline over recent decades,<sup>173</sup> as production of chemicals such as PCB's have been prohibited in many parts of the world.<sup>174</sup>

## Seasonality

Some authors have proposed that cryptorchidism occurs in cycles according to calendar period of birth – with seasonal peaks that occur between September to November and again sometime between January and May (in the Northern Hemisphere).<sup>1,81,87,88,179–181</sup> While it has been suggested that these seasonal peaks may coincide with hypothesised seasonal peaks in testosterone levels,<sup>81</sup> this has not been substantiated.

## Diet

Giordano et al.<sup>93</sup> found an association between maternal consumption of smoked food products during pregnancy (adjusted OR: 2.46, 95% CI 1.15–5.29), and suggested that this may be evidence of a link between potentially-toxic components of food and disruption of endocrine processes. Brantsæter et al. recently observed no association between maternal consumption of organic foods during pregnancy and subsequent development of cryptorchidism in the son.<sup>182</sup>

There is conflicting evidence in terms of the existence of an association between maternal use of caffeine and development of cryptorchidism: Berkowitz and Lapinski<sup>94</sup> observed no association between either maternal coffee (crude OR: 0.97, 95% CI 0.58–1.63 for  $\geq 1$  cup per day) or tea (OR: 1.04, 95% CI 0.59–1.81 for  $\geq 1$  cup per day) drinking during pregnancy and cryptorchidism development, while Mongraw-Chaffin et al.<sup>95</sup> observed that coffee drinkers appeared more likely to have sons with cryptorchidism (adjusted OR: 1.43, 95% CI 1.06–1.93 for 3 cups of coffee/day). However, Mongraw-Chaffin et al.<sup>95</sup> suggested that, if Berkowitz and Lapinski<sup>94</sup> had set their threshold for coffee use higher than  $\geq 1$  cup/day, they too may have observed an association between caffeine exposure and cryptorchidism development. Further work is required to substantiate this association – particularly given the abrupt rise in the consumption of caffeinated ‘energy’ drinks over the past decade.<sup>183</sup>

## Birth presentation

In 1983, Swerdlow and colleagues<sup>84</sup> observed that boys born with cryptorchidism were considerably more likely to present in the breech position at the time of delivery than non-cryptorchid boys. The authors postulated that this might suggest causality between the obstetric trauma of a breech pregnancy and cryptorchidism, citing evidence from previous studies that had found testicular bruising and lesions among children who had presented in the breech position.<sup>184–186</sup> The authors also suggested this observation was further grounds for protective Caesarean section to deliver these children.<sup>84</sup>

However, while multiple authors have also observed an association between cryptorchidism and breech presentation<sup>89814868187188</sup> and/or mode of delivery,<sup>689818878,8776</sup> it is possible that this association is primarily driven by shared aetiology rather than direct causality.<sup>89</sup> In other words, the intrauterine factors that cause a child to settle into breech could be the same

(or similar) to those that lead to maldescent of the testes; a theory supported by the observations of Damgaard et al.,<sup>68</sup> who found that the association between breech presentation and cryptorchidism remained strong even when adjusted for multiple covariates, including mode of delivery (adjusted OR: 2.59, 95% CI 1.12–5.97). The authors suggest that the association between breech presentation and cryptorchidism may actually be an indirect marker of placental impairment.<sup>68</sup>

## Gestational factors

Cryptorchidism has been consistently shown to be strongly associated with low birth weight, gestational age, and size for gestational age.<sup>5,34,48,81,83,89,189,190,86,88,77,58,64,01,87,28,24,80,77,8,92</sup> For example, recent observations from a New Zealand birth cohort showed that the prevalence of all three of these markers within boys with orchidopexy-confirmed cryptorchidism was approximately twice that observed among non-cryptorchid boys.<sup>189</sup> In addition, relative foetal growth restriction is also associated with cryptorchidism: Jensen et al.<sup>34</sup> observed that a twin born with cryptorchidism was, on average, 136g lighter (95% CI 70–202) than a non-cryptorchid male twin.

In combination, these observations suggest that these could be risk factors for cryptorchidism; however, rather than being risk factors *per se*, birth weight and fetal growth restriction may either have a shared aetiology with cryptorchidism, or be on the causal pathway between causative factors and cryptorchidism. In this case, the true aetiological factors would be exposures in the intrauterine environment that affect foetal development – likely reflecting a combination of the genetic and/or environmental exposures discussed elsewhere in this review. Low birth weight, for example, may be the result of a multitude of maternal factors – such as smoking during pregnancy, nutrition, pre-pregnancy weight and age;<sup>191,192</sup> thus, it is difficult to determine the true nature of the association between these markers of gestation and testicular maldescent.

## Twinning

Weidner et al.<sup>86</sup> observed a protective effect among twin boys (compared to singletons) even after adjusting for birthweight (adjusted OR: 0.76, 95% CI 0.63–0.92) – while Jensen et al.<sup>193</sup> noted that the rate of concordance (i.e. cryptorchidism occurrence in a pair of brothers) is substantially higher among twin boy pairs compared to full brother pairs (from separate pregnancies) – but not different between mono- and dizygotic twins (concordance rate: full brother pairs 8.8%; dizygotic twin pairs 24.1%; monozygotic twin pairs 27.3%). This suggests that this concordance may more strongly related to the shared intrauterine environment, rather than a strong genetic component. Consistent with this, Schnack et al.,<sup>194</sup> estimated that the risk of cryptorchidism concordance in male-male twin pairs was 2.6 times higher than what would be expected from genetic contributions alone.

## Genetics

Genes that encode the molecules that facilitate testicular descent could be related to the risk of cryptorchidism;<sup>195</sup> for example, experimental studies have shown that ‘knocking-out’ the

gene that encodes *INSL3* will result in bilateral cryptorchidism.<sup>195</sup> It follows, then, that if abnormalities in these genes are handed from mother or father to son – and/or if epigenetic aberrations cause such abnormalities post-conception – then testicular descent will be directly affected by a genetic (or epigenetic) pathway.

In humans, there is evidence that brothers and sons of men both with cryptorchidism are at increased risk of cryptorchidism: some authors have shown an increased familial risk that declines with decreasing degree of relativity.<sup>6,196,187,188</sup> Jensen et al.<sup>193</sup> and Schnack et al.<sup>194</sup> both observed substantially higher concordance in cryptorchidism rates among maternal half-brothers compared to paternal half-brothers (concordance rate: maternal half-brothers 6%, paternal half-brothers 3.4%) – with the authors suggesting that given this observation (and the aforementioned observation regarding twinning), future aetiological work should focus on maternal genes (particularly the X chromosome) and the intrauterine environment.<sup>193</sup>

Variants in more than 15 genes have thus far been implicated in the development of cryptorchidism in humans via candidate gene studies (see Supplementary Material 2); however, only one genome-wide association study (GWAS) has been performed in ‘non-syndromic’ cryptorchidism (i.e. cryptorchidism in the absence of other congenital anomalies).<sup>197</sup> In a GWAS of 844 boys with cryptorchidism and 2,718 controls, no individual SNPs reached a level of genome-wide significance. Pathway analysis, however, suggested that loci important in cytoskeleton-dependent function may be of importance. The authors noted that their findings might reflect the fact that susceptibility to this disease is highly heterogeneous and possibly driven by environmental causes and/or rare genetic variants.<sup>197</sup>

With respect to the latter, rare mutations in *INSL3* and its receptor *RXFP2* have been reported at low frequencies (1–4%) in boys born with cryptorchidism,<sup>198,199</sup> while rare mutations have also been found in *NR5A1*, which is involved in several reproductive processes.<sup>200</sup> However, given the rarity of these mutations, they can only explain a very small proportion of cryptorchidism cases.

It is possible that inherited genetic variants may make an individual more or less susceptible to endocrine disruption via pathways such as exposure to chemicals, by disrupting the metabolism of these elements. For example an (albeit un-replicated) association reported by Qin et al.,<sup>201</sup> was with a variant of the *Aryl hydrocarbon receptor nuclear translocator 2* (*ARNT2*) gene (OR for minor homozygous genotype rs5000770 [AA vs. GG]: 3.5, 95% CI 1.7–7.3). This gene is part of a family of transcription factors that, among other roles, regulates several physiological pathways including responses to environmental contaminants. In this case, the likely causal mechanism by which genetic traits of the individual are influencing the likelihood of cryptorchidism is via interaction with environmental exposures – with this interaction leading to a ‘supra-multiplicative’ increase in cryptorchidism risk, beyond that which might be expected based on the individual associations. Such phenomena are referred to as non-additive (multiplicative) gene-environment interactions. There is, however, no evidence yet that such interactions exist in cryptorchidism.

It is important to note that a number of discoveries in the cryptorchidism context – for example, regarding the role of *INSL3* in testicular descent – were made using animal models, and that the way in which testicular descent occurs in non-human models varies in several important respects to the same process in humans. For example, in humans the *processus vaginalis* (Fig. 1) disappears following testicular descent; while in rodents, it remains intact – enabling the testis to ascend back into the peritoneum later in life.<sup>18</sup> Because of key differences in testicular descent between species, findings in animal models are not necessarily transferable to humans – unless, as in the case of *INSL3*, evidence exists from both experimental (non-human) models<sup>195</sup> and human studies.<sup>198,199</sup>

## Ethnicity

There is some evidence of varying risk of cryptorchidism by ethnic grouping. In the United States, McGlynn et al.<sup>82</sup> observed that cryptorchidism was somewhat less likely in Black males compared to White males; while in New Zealand, M ori males are 20% more likely to be born with cryptorchidism than the non-M ori/Pacific/Asian population (adjusted RR: 1.20, 95% CI 1.11–1.30), while Pacific (0.89, 95% CI 0.80–0.99) and Asian (0.68, 95% CI 0.59–0.79) males have lower risk.<sup>189</sup> It has also been noted in New Zealand that ethnic trends in cryptorchidism incidence mirror those observed for testicular cancer.<sup>202,203</sup>

It is possible that these ethnic trends are driven by predisposing genetic variants that are present in some ethnic groups but not others – however, it is important to note that ethnicity is a social construct, to which individuals self-identify (or are identified by their parents, in the case of newborns). However it is possible that individuals within a specific ethnic group are more likely to share some common ancestry, which may be associated with a high likelihood of specific predisposing genetic variants.

## Recommendations for future work

### Further systematic reviews and meta-analyses

For those risk factors in which there is a body of epidemiological evidence, additional high-quality systematic reviews, which include quality assessment of the studies, and meta-analyses are required in order to provide best-estimates regarding the current state of evidence with respect to a given exposure. The heterogeneity of exposure measurement (and outcome measurement, for that matter) will present a challenge for these studies.

### Strengthening causal inference

Future work should aim at using approaches that can strengthen casual inference by separating spurious associations from causal effects. For example, future work aiming to provide further evidence for a causal role for smoking and alcohol in the development of cryptorchidism should consider using Mendelian randomisation. Using this approach, researchers could use genetic variants known to influence the risk of smoking and alcohol consumption, and assess their association with cryptorchidism. This approach is not subject to experimental biases (including social desirability bias), and as such represents a viable alternative means of testing the observational associations for causality. While the rarity of

cryptorchidism may affect the usefulness of this method in this context, it is certainly worthy of further consideration.

### Development of a cryptorchidism consortium

As noted throughout this review, many individual studies investigating specific risk factors for cryptorchidism are underpowered to identify potential associations. There is therefore a great need for further high-quality studies that are well-powered and designed with sufficient detail to allow exploration of dose-response relationships and adjustment for multiple confounders, ideally with inclusion of genetic sampling to contribute to a large GWAS in cryptorchidism with thousands of cases. A key area of future emphasis in this regard will be the combination of study datasets across international contexts, such that these comprehensive multivariate analyses can be performed. This consortium dataset would help in the identification causal factors, but also allow us to estimate prevalence of cryptorchidism in a standardised fashion across different countries, which would be highly informative.

### Conclusions

Painting a picture of the factors that lead to maldescent of the testes is a difficult task, as evidenced by the uncertainties noted in this review. We have presented a list of putative risk factors in Box 1, which lists risk factors according to the likelihood that they are associated with cryptorchidism development. However, there are few instances in which there is consistent evidence with respect to a given exposure; and in those cases where evidence appears unequivocal – for example, the relationship between cryptorchidism and gestational measures such as low birth weight – the measured exposure actually represents exposure(s) that we don't yet fully understand in the cryptorchidism context. Perhaps these caveats provide a clue as to why a concrete understanding of the aetiology of this disease remains elusive: in a situation where myriad (and often ubiquitous) exposures have been associated with cryptorchidism, it is likely that the causal roots of this condition are multifactorial and highly variable between individuals. Rather than a handful of candidate exposures being responsible for the vast majority of cases, perhaps the relative importance of each risk factor varies considerably between mother/son pairs depending on an array of genetic, maternal, placental and foetal factors – all of which could vary between regional contexts. In short, the complexity of (and mystery surrounding) the aetiology of this disease is perhaps an appropriate reflection of the complexity of the biological mechanisms that drive testicular descent in the first place.

#### Box 1

##### Putative risk factors associated with cryptorchidism

##### Likely to be associated

- Maternal smoking during pregnancy <sup>9446589758092824076104105100,106</sup>
- Birth measures (birth weight, gestational age, size for gestational age)  
5,8,34,40,48,68,75,77,80–84,86–89,92,187,189,190

- Family history of cryptorchidism <sup>6,86,187,188,196</sup>
- Rare genetic variants (e.g. mutations at *INSL3* <sup>198,199</sup>)

#### Unlikely to be associated

- Assisted reproduction <sup>63,70–74</sup>
- Diet during pregnancy <sup>182</sup>
- Birth presentation <sup>68</sup>

#### Inconsistent or limited evidence of an association

- Intrauterine exposure to high levels of endogenous hormones (e.g. estrogen <sup>42–50</sup>)
- Maternal health (see Supplementary Material 1)
- Parity <sup>767886657587888948838477</sup>
- Maternal age <sup>75,767778798081686546778283767784854882</sup>
- Maternal alcohol consumption during pregnancy <sup>93799499966467895769289100</sup>
- Paternal smoking during pregnancy <sup>75,79,80,104,105</sup>
- Maternal use of medications not related to pregnancy <sup>46,113–120</sup>
- Maternal use of pregnancy-related medications <sup>76,78,110111</sup>
- Maternal use of analgesics <sup>6,46,78,94,122–126</sup>
- Maternal recreational drug use <sup>94</sup>
- Maternal occupational exposure to endocrine-disrupting chemicals <sup>98,138–140,143</sup>
- Paternal occupational exposure to endocrine-disrupting chemicals <sup>75,98,141,142</sup>
- Geographic proximity to areas of intensive use of endocrine-disrupting chemicals <sup>147–151</sup>
- Maternal or childhood direct exposure to endocrine-disrupting chemicals <sup>56,60,152–157,159,160,163,164,168,169,172–174,176–178</sup>
- Seasonality <sup>1,81,87,88,179–181</sup>
- Maternal caffeine consumption <sup>94,95</sup>
- Ethnicity <sup>82,189</sup>

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## References

1. Ansell PE, et al. Cryptorchidism: A prospective study of 7500 consecutive male births, 1984–8. *Archives of Disease in Childhood*. 1992; 67:892–899. [PubMed: 1355643]
2. Abdullah NA, et al. Birth prevalence of cryptorchidism and hypospadias in northern England, 1993–2000. *Archives of Disease in Childhood*. 2007; 92:576–579. DOI: 10.1136/adc.2006.102913 [PubMed: 17142312]
3. Berkowitz GS, et al. Prevalence and natural history of cryptorchidism. *Pediatrics*. 1993; 92:44–49. [PubMed: 8100060]
4. Pierik FH, et al. The cryptorchidism prevalence among infants in the general population of Rotterdam, the Netherlands. *International Journal of Andrology*. 2005; 28:248–252. DOI: 10.1111/j.1365-2605.2005.00538.x [PubMed: 16048638]
5. Preikša RT, et al. Higher than expected prevalence of congenital cryptorchidism in Lithuania: A study of 1204 boys at birth and 1 year follow-up. *Human Reproduction*. 2005; 20:1928–1932. DOI: 10.1093/humrep/deh887 [PubMed: 15860495]
6. Wagner-Mahler K, et al. Prospective study on the prevalence and associated risk factors of cryptorchidism in 6246 newborn boys from Nice area, France. *International Journal of Andrology*. 2011; 34:e499–e510. DOI: 10.1111/j.1365-2605.2011.01211.x [PubMed: 21831232]
7. Boisen KA, et al. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. *Lancet*. 2004; 363:1264–1269. DOI: 10.1016/S0140-6736(04)15998-9 [PubMed: 15094270]
8. Ghirri P, et al. Incidence at birth and natural history of cryptorchidism: A study of 10,730 consecutive male infants. *Journal of Endocrinological Investigation*. 2002; 25:709–715. [PubMed: 12240903]
9. Barthold JS, Gonzalez R. The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. *Journal of Urology*. 2003; 170:2396–2401. DOI: 10.1097/01.ju.0000095793.04232.d8 [PubMed: 14634436]
10. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. *World Journal of Urology*. 2004; 22:2–14. DOI: 10.1007/s00345-004-0398-8 [PubMed: 15034740]
11. Lip SZL, Murchison LED, Cullis PS, Govan L, Carachi R. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. *Archives of Disease in Childhood*. 2013; 98:20–26. [PubMed: 23193201]
12. Cook MB, et al. A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer - experiences of the son. *International Journal of Epidemiology*. 2010; 39:1605–1618. [PubMed: 20660640]
13. Kanto S, et al. Risk factors in past histories and familial episodes related to development of testicular germ cell tumor. *International journal of urology : official journal of the Japanese Urological Association*. 2004; 11:640–646. DOI: 10.1111/j.1442-2042.2004.00853.x [PubMed: 15285755]
14. Prener A, Engholm G, Jensen OM. Genital anomalies and risk for testicular cancer in Danish men. *Epidemiology*. 1996; 7:14–19. [PubMed: 8664395]
15. Lee PA, et al. Paternity after unilateral cryptorchidism: A controlled study. *Pediatrics*. 1996; 98:676–679. [PubMed: 8885945]
16. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. *Human Reproduction*. 2001; 16:972–978. [PubMed: 11331648]
17. Nordenvall AS, Frisén L, Nordenström A, Lichtenstein P, Nordenskjöld A. Population based nationwide study of hypospadias in Sweden, 1973 to 2009: Incidence and risk factors. *Journal of Urology*. 2014; 191:783–789. [PubMed: 24096117]
18. Hutson, JM., Thorup, JM., Beasley, SW. *Descent of the testis*. 2. Springer International Publishing; 2016.
19. Abeyaratne MR, Aherne WA, Scott JE. The vanishing testis. *Lancet*. 1969; 2:822–824. [PubMed: 4186283]

20. Kollin C, Karpe B, Hesser U, Granholm T, Ritzén EM. Surgical Treatment of Unilaterally Undescended Testes: Testicular Growth After Randomization to Orchiopexy at Age 9 Months or 3 Years. *The Journal of Urology*. 2007; 178:1589–1593. DOI: 10.1016/j.juro.2007.03.173 [PubMed: 17707045]
21. Kolon TF, et al. Evaluation and treatment of Cryptorchidism: AUA guideline. *Journal of Urology*. 2014; 192:337–345. DOI: 10.1016/j.juro.2014.05.005 [PubMed: 24857650]
22. Jensen MS, et al. Age at cryptorchidism diagnosis and orchiopexy in Denmark: a population based study of 508,964 boys born from 1995–2009. *The Journal of Urology*. 2011; 186:1595–1600. [PubMed: 21855929]
23. Martin Ritzén E. Undescended testes: A consensus on management. *European Journal of Endocrinology*. 2008; 159:S87–S90. [PubMed: 18728121]
24. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at Surgery for Undescended Testis and Risk of Testicular Cancer. *New England Journal of Medicine*. 2007; 356:1835–1841. DOI: 10.1056/NEJMoa067588 [PubMed: 17476009]
25. Wood HM, Elder JS. Cryptorchidism and Testicular Cancer: Separating Fact From Fiction. *Journal of Urology*. 2009; 181:452–461. DOI: 10.1016/j.juro.2008.10.074 [PubMed: 19084853]
26. Akre O, Pettersson A, Richiardi L. Risk of contralateral testicular cancer among men with unilaterally undescended testis: A meta analysis. *International Journal of Cancer*. 2009; 124:687–689. [PubMed: 18973229]
27. Pottern LM, et al. Testicular cancer risk among young men: Role of cryptorchidism and inguinal hernia. *Journal of the National Cancer Institute*. 1985; 74:377–381. [PubMed: 2857796]
28. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. *Endocrine Reviews*. 1997; 18:259–280. [PubMed: 9101140]
29. Toppari J, Kaleva M, Virtanen HE. Trends in the incidence of cryptorchidism and hypospadias, and methodological limitations of registry-based data. *Human Reproduction Update*. 2001; 7:282–286. DOI: 10.1093/humupd/7.3.282 [PubMed: 11392374]
30. Chilvers C, Forman D, Pike MC, Fogelman K, Wadsworth MEJ. APPARENT DOUBLING OF FREQUENCY OF UNDESCENDED TESTIS IN ENGLAND AND WALES IN 1962–81. *The Lancet*. 1984; 324:330–332. DOI: 10.1016/S0140-6736(84)92697-7
31. Bonney T, Southwell B, Donnath S, Newgreen D, Hutson J. Orchiopexy trends in the paediatric population of Victoria, 1999–2006. *Journal of Pediatric Surgery*. 2009; 44:427–431. DOI: 10.1016/j.jpedsurg.2008.10.099 [PubMed: 19231549]
32. Capello SA, Giorgi LJ Jr, Kogan BA. Orchiopexy practice patterns in New York State from 1984 to 2002. *J Urol*. 2006; 176:1180–1183. DOI: 10.1016/j.juro.2006.04.052 [PubMed: 16890721]
33. Richiardi L, Vizzini L, Nordenskjold A, Pettersson A, Akre O. Rates of orchiopexies in Sweden: 1977–1991. *Int J Androl*. 2009; 32:473–478. DOI: 10.1111/j.1365-2605.2008.00881.x [PubMed: 18336536]
34. Jensen MS, et al. Cryptorchidism and hypospadias in a cohort of 934,538 danish boys: The role of birth weight, gestational age, body dimensions, and fetal growth. *American Journal of Epidemiology*. 2012; 175:917–925. DOI: 10.1093/aje/kwr421 [PubMed: 22454385]
35. Jensen MS, et al. Age at cryptorchidism diagnosis and orchiopexy in Denmark: A population based study of 508,964 boys born from 1995 to 2009. *Journal of Urology*. 2011; 186:1595–1600. DOI: 10.1016/j.juro.2011.03.070 [PubMed: 21855929]
36. Wohlfahrt-Veje C, et al. Acquired cryptorchidism is frequent in infancy and childhood. *Int J Androl*. 2009; 32:423–428. DOI: 10.1111/j.1365-2605.2009.00946.x [PubMed: 19515170]
37. Hutson J, Li R, Southwell B, Newgreen D, Cousinery M. Regulation of testicular descent. *Pediatric Surgery International*. 2015; 31:317–325. DOI: 10.1007/s00383-015-3673-4 [PubMed: 25690562]
38. Jensen MS, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology*. 2010; 21:779–785. DOI: 10.1097/EDE.0b013e3181f20bed [PubMed: 20805751]
39. Barteczko KJ, Jacob MI. The testicular descent in human. Origin, development and fate of the gubernaculum Hunteri, processus vaginalis peritonei, and gonadal ligaments. *Advances in anatomy, embryology, and cell biology*. 2000; 156

40. Akre O, Lipworth L, Cnattingius S, Sparén P, Ekblom A. Risk factor patterns for cryptorchidism and hypospadias. *Epidemiology*. 1999; 10:364–369. [PubMed: 10401869]
41. Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? *The Lancet*. 1993; 341:1392–1396. DOI: 10.1016/0140-6736(93)90953-E
42. Bernstein L, et al. Maternal hormone levels in early gestation of cryptorchid males: A case-control study. *British Journal of Cancer*. 1988; 58:379–381. [PubMed: 2902875]
43. McGlynn KA, et al. Maternal hormone levels and risk of cryptorchism among populations at high and low risk of testicular germ cell tumors. *Cancer Epidemiology Biomarkers and Prevention*. 2005; 14:1732–1737. DOI: 10.1158/1055-9965.EPI-05-0128
44. Burton MH, Davies TW, Raggatt PR. Undescended testis and hormone levels in early pregnancy. *Journal of Epidemiology and Community Health*. 1987; 41:127–129. [PubMed: 2888831]
45. Key TJA, et al. A case - Control study of cryptorchidism and maternal hormone concentrations in early pregnancy. *British Journal of Cancer*. 1996; 73:698–701. [PubMed: 8605110]
46. Davies TW, Williams DRR, Whitaker AH. Risk factors for undescended testis. *International Journal of Epidemiology*. 1986; 15:197–201. DOI: 10.1093/ije/15.2.197 [PubMed: 2873109]
47. Beard CM, Melton LJ, O’Fallon WM, Noller KL, Benson RC. Cryptorchism and maternal estrogen exposure. *American Journal of Epidemiology*. 1984; 120:707–716. [PubMed: 6149686]
48. Jones ME, Swerdlow AJ, Griffith M, Goldacre MJ. Prenatal risk factors for cryptorchidism: A record linkage study. *Paediatric and Perinatal Epidemiology*. 1998; 12:383–396. DOI: 10.1046/j.1365-3016.1998.00144.x [PubMed: 9805712]
49. Boyd HA, et al. Maternal serum alpha-fetoprotein level during pregnancy and isolated cryptorchidism in male offspring. *American Journal of Epidemiology*. 2006; 164:478–486. DOI: 10.1093/aje/kwj219 [PubMed: 16790515]
50. Chedane C, Puissant H, Weil D, Rouleau S, Coutant R. Association between altered placental human chorionic gonadotrophin (hCG) production and the occurrence of cryptorchidism: A retrospective study. *BMC Pediatrics*. 2014; 14
51. Mizuno K, et al. Altered expression and localization of estrogen receptors alpha and beta in the testes of a cryptorchid rat model. *Urology*. 2011; 77:251.e251–251.e256. DOI: 10.1016/j.urology.2010.06.035 [PubMed: 20951417]
52. Mizuno K, et al. Influence for testicular development and histological peculiarity in the testes of flutamide-induced cryptorchid rat model. *International Journal of Urology*. 2007; 14:67–72. DOI: 10.1111/j.1442-2042.2006.01654.x [PubMed: 17199863]
53. Van der Schoot P. Disturbed testicular descent in the rat after prenatal exposure to the antiandrogen flutamide. *Journal of Reproduction and Fertility*. 1992; 96:483–496. [PubMed: 1364084]
54. Abbo O, et al. Male infants with hypospadias and/or cryptorchidism show a lower 2D/4D digit ratio than normal boys. *Archives of Disease in Childhood*. 2015; 100:643–647. DOI: 10.1136/archdischild-2014-306454 [PubMed: 25688099]
55. Fénichel P, et al. Cord blood Insulin-like peptide 3 (INSL3) but not testosterone is reduced in idiopathic cryptorchidism. *Clinical Endocrinology*. 2015; 82:242–247. DOI: 10.1111/cen.12500 [PubMed: 24826892]
56. Chevalier N, et al. A negative correlation between insulin-like peptide 3 and bisphenol A in human cord blood suggests an effect of endocrine disruptors on testicular descent during fetal development. *Human Reproduction*. 2015; 30:447–453. DOI: 10.1093/humrep/deu340 [PubMed: 25527819]
57. Scott HM, Mason JI, Sharpe RM. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. *Endocr Rev*. 2009; 30:883–925. DOI: 10.1210/er.2009-0016 [PubMed: 19887492]
58. Zimmermann S, et al. Targeted disruption of the *Insl3* gene causes bilateral cryptorchidism. *Molecular endocrinology (Baltimore, Md)*. 1999; 13:681–691. DOI: 10.1210/mend.13.5.0272
59. Bay K, Andersson AM. Human testicular insulin-like factor 3: in relation to development, reproductive hormones and andrological disorders. *Int J Androl*. 2011; 34:97–109. DOI: 10.1111/j.1365-2605.2010.01074.x [PubMed: 20550598]

60. Toft G, et al. Perfluorooctane sulfonate concentrations in amniotic fluid, biomarkers of fetal leydig cell function, and cryptorchidism and hypospadias in Danish boys (1980–1996). *Environmental Health Perspectives*. 2016; 124:151–156. DOI: 10.1289/ehp.1409288 [PubMed: 26046833]
61. Klemetti R, et al. Children born after assisted fertilization have an increased rate of major congenital anomalies. *Fertility and Sterility*. 2005; 84:1300–1307. DOI: 10.1016/j.fertnstert.2005.03.085 [PubMed: 16275218]
62. Pinborg A, Henningsen AKA, Malchau SS, Loft A. Congenital anomalies after assisted reproductive technology. *Fertility and Sterility*. 2013; 99:327–332. DOI: 10.1016/j.fertnstert.2012.12.001 [PubMed: 23290686]
63. Funke S, et al. Male reproductive tract abnormalities: More common after assisted reproduction? *Early Human Development*. 2010; 86:547–550. DOI: 10.1016/j.earlhumdev.2010.06.015 [PubMed: 20674196]
64. Bang JK, et al. Does infertility treatment increase male reproductive tract disorder? *Urology*. 2013; 81:644–648. DOI: 10.1016/j.urology.2012.12.003 [PubMed: 23452810]
65. Fedder J, Loft A, Parner ET, Rasmussen S, Pinborg A. Neonatal outcome and congenital malformations in children born after ICSI with testicular or epididymal sperm: A controlled national cohort study. *Human Reproduction*. 2013; 28:230–240. DOI: 10.1093/humrep/des377 [PubMed: 23154066]
66. Kermani RM, et al. Congenital anomalies in infants conceived by assisted reproductive techniques. *Archives of Iranian Medicine*. 2012; 15:228–231. [PubMed: 22424041]
67. Yan J, et al. Birth defects after assisted reproductive technologies in China: Analysis of 15,405 offspring in seven centers (2004 to 2008). *Fertility and Sterility*. 2011; 95:458–460. DOI: 10.1016/j.fertnstert.2010.08.024 [PubMed: 20850722]
68. Damgaard IN, et al. Risk factors for congenital cryptorchidism in a prospective birth cohort study. *PLoS ONE*. 2008; 3
69. Hansen M, Kurinczuk JJ, De Klerk N, Burton P, Bower C. Assisted reproductive technology and major birth defects in Western Australia. *Obstetrics and Gynecology*. 2012; 120:852–863. DOI: 10.1097/AOG.0b013e318269c282 [PubMed: 22996103]
70. Halliday JL, et al. Increased risk of blastogenesis birth defects, arising in the first 4 weeks of pregnancy, after assisted reproductive technologies. *Human reproduction (Oxford, England)*. 2010; 25:59–65. DOI: 10.1093/humrep/dep364
71. Zhu JL, Basso O, Obel C, Bille C, Olsen J. Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. *British Medical Journal*. 2006; 333:679–681. DOI: 10.1136/bmj.38919.495718.AE [PubMed: 16893903]
72. Simpson JL. Birth defects and assisted reproductive technologies. *Seminars in fetal & neonatal medicine*. 2014; 19:177–182. DOI: 10.1016/j.siny.2014.01.001 [PubMed: 24559658]
73. Massaro PA, Maclellan DL, Anderson PA, Romao RLP. Does intracytoplasmic sperm injection pose an increased risk of genitourinary congenital malformations in offspring compared to in vitro fertilization? A systematic review and meta-analysis. *Journal of Urology*. 2015; 193:1837–1842. DOI: 10.1016/j.juro.2014.10.113 [PubMed: 25813561]
74. Källén B, Finnström O, Nygren KG, Olausson PO. In vitro fertilization (IVF) in Sweden: Risk for congenital malformations after different IVF methods. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2005; 73:162–169. DOI: 10.1002/bdra.20107 [PubMed: 15678490]
75. Pierik FH, Burdorf A, Deddens JA, Juttman RE, Weber RFA. Maternal and paternal risk factors for cryptorchidism and hypospadias: A case-control study in newborn boys. *Environmental Health Perspectives*. 2004; 112:1570–1576. DOI: 10.1289/ehp.7243 [PubMed: 15531444]
76. McBride ML, Van Den Steen N, Lamb CW, Gallagher RP. Maternal and gestational factors in cryptorchidism. *International Journal of Epidemiology*. 1991; 20:964–970. DOI: 10.1093/ije/20.4.964 [PubMed: 1686874]
77. Mavrogenis S, Urbán R, Czeizel AE. Characteristics of boys with the so-called true undescended testis diagnosed at the third postnatal month - A population-based case-control study. *Journal of Maternal-Fetal and Neonatal Medicine*. 2015; 28:1152–1157. DOI: 10.3109/14767058.2014.947569 [PubMed: 25053192]

78. Mori M, Davies TW, Tsukamoto T, Kumamoto Y, Fukuda K. Maternal and other factors of cryptorchidism--a case-control study in Japan. *Kurume Medical Journal*. 1992; 39:53–60. [PubMed: 1357225]
79. Kurahashi N, et al. Parental and neonatal risk factors for cryptorchidism. *Medical Science Monitor*. 2005; 11:CR274–CR283. [PubMed: 15917718]
80. Zakaria M, Azab S, El Baz M, Fawaz L, Bahagat A. Cryptorchidism in Egyptian neonates. *Journal of Pediatric Urology*. 2013; 9:815–819. DOI: 10.1016/j.jpuro.2012.10.024 [PubMed: 23218756]
81. Berkowitz GS, Lapinski RH, Godbold JH, Dolgin SE, Holzman IR. Maternal and neonatal risk factors for cryptorchidism. *Epidemiology*. 1995; 6:127–131. [PubMed: 7742397]
82. McGlynn KA, Graubard BI, Klebanoff MA, Longnecker MP. Risk factors for cryptorchism among populations at differing risks of testicular cancer. *International Journal of Epidemiology*. 2006; 35:787–795. DOI: 10.1093/ije/dyl024 [PubMed: 16492711]
83. Møller H, Skakkebaek NE. Testicular cancer and cryptorchidism in relation to prenatal factors: Case-control studies in Denmark. *Cancer Causes and Control*. 1997; 8:904–912. DOI: 10.1023/A:1018472530653 [PubMed: 9427433]
84. Swerdlow AJ, Wood KH, Smith PG. A case-control study of the aetiology of cryptorchidism. *Journal of Epidemiology and Community Health*. 1983; 37:238–244. [PubMed: 6137506]
85. Csermely G, Susánszky É, Czeizel AE. Association of young and advanced age of pregnant women with the risk of isolated congenital abnormalities in Hungary - A population-based case-matched control study. *Journal of Maternal-Fetal and Neonatal Medicine*. 2015; 28:436–442. DOI: 10.3109/14767058.2014.918946 [PubMed: 24766076]
86. Weidner IS, Møller H, Jensen TK, Skakkebaek NE. Risk factors for cryptorchidism and hypospadias. *Journal of Urology*. 1999; 161:1606–1609. DOI: 10.1016/S0022-5347(05)68992-6 [PubMed: 10210427]
87. Hjertqvist M, Damber JE, Bergh A. Cryptorchidism: A registry based study in Sweden on some factors of possible aetiological importance. *Journal of Epidemiology and Community Health*. 1989; 43:324–329. [PubMed: 2575645]
88. Mayr JM, Lawrenz K, Berghold A. Undescended testicles: An epidemiological review. *Acta Paediatrica, International Journal of Paediatrics*. 1999; 88:1089–1093. DOI: 10.1080/08035259950168144
89. Biggs ML, Baer A, Critchlow CW. Maternal, delivery, and perinatal characteristics associated with cryptorchidism: A population-based case-control study among births in Washington State. *Epidemiology*. 2002; 13:197–204. DOI: 10.1097/00001648-200203000-00015 [PubMed: 11880761]
90. Emanuele N, Emanuele MA. The endocrine system alcohol alters critical hormonal balance. *Alcohol Research and Health*. 1997; 21:53–64.
91. Emanuele MA, Emanuele N. Alcohol and the male reproductive system. *Alcohol Research and Health*. 2001; 25:282–287. [PubMed: 11910706]
92. Brouwers MM, et al. Risk factors for undescended testis. *Journal of Pediatric Urology*. 2012; 8:59–66. DOI: 10.1016/j.jpuro.2010.11.001 [PubMed: 21115274]
93. Giordano F, et al. Maternal diet and the risk of hypospadias and cryptorchidism in the offspring. *Paediatric and Perinatal Epidemiology*. 2008; 22:249–260. DOI: 10.1111/j.1365-3016.2007.00918.x [PubMed: 18426520]
94. Berkowitz GS, Lapinski RH. Risk factors for cryptorchidism: A nested case-control study. *Paediatric and Perinatal Epidemiology*. 1996; 10:39–51. [PubMed: 8746430]
95. Mongraw-Chaffin ML, Cohn BA, Cohen RD, Christianson RE. Maternal smoking, alcohol consumption, and caffeine consumption during pregnancy in relation to a son's risk of persistent cryptorchidism: A prospective study in the child health and development studies cohort, 1959–1967. *American Journal of Epidemiology*. 2008; 167:257–261. DOI: 10.1093/aje/kwm311 [PubMed: 18024986]
96. Jensen MS, Bonde JP, Olsen J. Prenatal alcohol exposure and cryptorchidism. *Acta Paediatrica, International Journal of Paediatrics*. 2007; 96:1681–1685. DOI: 10.1111/j.1651-2227.2007.00506.x

97. Damgaard IN, et al. Cryptorchidism and maternal alcohol consumption during pregnancy. *Environmental Health Perspectives*. 2007; 115:272–277. DOI: 10.1289/ehp.9608 [PubMed: 17384777]
98. Carbone P, et al. The possible role of endocrine disrupting chemicals in the aetiology of cryptorchidism and hypospadias: A population-based case-control study in rural Sicily. *International Journal of Andrology*. 2007; 30:3–13. DOI: 10.1111/j.1365-2605.2006.00703.x [PubMed: 16824044]
99. Strandberg-Larsen K, Jensen MS, Ramlau-Hansen CH, Grønþæk M, Olsen J. Alcohol binge drinking during pregnancy and cryptorchidism. *Human Reproduction*. 2009; 24:3211–3219. DOI: 10.1093/humrep/dep325 [PubMed: 19767622]
100. Zhang L, et al. Maternal gestational smoking, diabetes, alcohol drinking, pre-pregnancy obesity and the risk of cryptorchidism: A systematic review and meta-analysis of observational studies. *PLoS ONE*. 2015; 10
101. Cnattingius S. The epidemiology of smoking during pregnancy: Smoking prevalence, maternal characteristics, and pregnancy outcomes. *Nicotine and Tobacco Research*. 2004; 6:S125–S140. DOI: 10.1080/14622200410001669187 [PubMed: 15203816]
102. Werler M. Maternal smoking and undescended testes: Reaching a tipping point. *Epidemiology*. 2007; 18:197–198. DOI: 10.1097/01.ede.0000254697.64626.1f [PubMed: 17301706]
103. Windham GC, Mitchell P, Anderson M, Lasley BL. Cigarette Smoking and Effects on Hormone Function in Premenopausal Women. *Environmental Health Perspectives*. 2005; 113:1285–1290. DOI: 10.1289/ehp.7899 [PubMed: 16203235]
104. Zhang J, Savitz DA, Schwingl PJ, Cai WW. A case-control study of paternal smoking and birth defects. *International Journal of Epidemiology*. 1992; 21:273–278. [PubMed: 1428480]
105. Jensen MS, Toft G, Thulstrup AM, Bonde JP, Olsen J. Cryptorchidism according to maternal gestational smoking. *Epidemiology*. 2007; 18:220–225. [PubMed: 17202869]
106. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: A systematic review based on 173 687 malformed cases and 11.7 million controls. *Human Reproduction Update*. 2011; 17:589–604. DOI: 10.1093/humupd/dmr022 [PubMed: 21747128]
107. Thorup J, Cortes D, Petersen BL. The Incidence of Bilateral Cryptorchidism is Increased and the Fertility Potential is Reduced in Sons Born to Mothers who Have Smoked During Pregnancy. *Journal of Urology*. 2006; 176:734–737. DOI: 10.1016/j.juro.2006.03.042 [PubMed: 16813933]
108. Gaspari L, et al. Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: A nested case-control study. *Human Reproduction*. 2011; 26:3155–3162. DOI: 10.1093/humrep/der283 [PubMed: 21868402]
109. Office on Smoking and Health. A report of the Surgeon General. US Department of Health and Human Services; Washington, DC: 1980. The health consequences of smoking for women.
110. Mavrogenis S, Urban R, Czeizel AE, Ács N. Possible association of maternal factors with the higher risk of isolated true undescended testis: A population-based case-control study. *Congenital Anomalies*. 2014; 54:178–183. DOI: 10.1111/cga.12061 [PubMed: 24754829]
111. Palmer JR, et al. Urogenital abnormalities in men exposed to diethylstilbestrol in utero: A cohort study. *Environmental Health: A Global Access Science Source*. 2009; 8
112. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. *AIDS*. 2009; 23:519–524. DOI: 10.1097/QAD.0b013e328326ca8e [PubMed: 19165088]
113. Ács N, Bánhidly F, Puhó EH, Czeizel AE. No association between vulvovaginitis-bacterial vaginosis, related drug treatments of pregnant women, and congenital abnormalities in their offspring - A population-based case-control study. *Central European Journal of Medicine*. 2008; 3:332–340. DOI: 10.2478/s11536-008-0027-9
114. Czeizel AE, Kazy Z, Puhó E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. *Scandinavian Journal of Infectious Diseases*. 2003; 35:830–835. DOI: 10.1080/00365540310017069 [PubMed: 14723358]
115. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *New England Journal of Medicine*. 2007; 356:2675–2683. DOI: 10.1056/NEJMoa067407 [PubMed: 17596601]

116. Ács N, Bánhidly F, Puhó EH, Czeizel AE. Senna treatment in pregnant women and congenital abnormalities in their offspring-A population-based case-control study. *Reproductive Toxicology*. 2009; 28:100–104. DOI: 10.1016/j.reprotox.2009.02.005 [PubMed: 19491001]
117. Bártfai Z, Somoskövi A, Puhó EH, Czeizel AE. No teratogenic effect of prenoxidiazine: A population-based case-control study. *Congenital Anomalies*. 2007; 47:16–21. DOI: 10.1111/j.1741-4520.2006.00136.x [PubMed: 17300686]
118. Kjør D, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: A case-time-control study. *Pharmacoepidemiology and Drug Safety*. 2007; 16:181–188. DOI: 10.1002/pds.1288 [PubMed: 16941718]
119. Dessens AB, et al. Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. *Teratology*. 2001; 64:181–188. DOI: 10.1002/tera.1063 [PubMed: 11598924]
120. Diav-Citrin O, et al. Pregnancy outcome after in utero exposure to valproate: Evidence of dose relationship in teratogenic effect. *CNS Drugs*. 2008; 22:325–334. DOI: 10.2165/00023210-200822040-00004 [PubMed: 18336060]
121. Mazaud-Guittot S, et al. Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. *Journal of Clinical Endocrinology and Metabolism*. 2013; 98:E1757–E1767. DOI: 10.1210/jc.2013-2531 [PubMed: 24030937]
122. Snijder CA, et al. Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadias in the offspring: The Generation R Study. *Human Reproduction*. 2012; 27:1191–1201. DOI: 10.1093/humrep/der474 [PubMed: 22301570]
123. Kristensen DM, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Human Reproduction*. 2011; 26:235–244. DOI: 10.1093/humrep/deq323 [PubMed: 21059752]
124. Jensen MS, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology*. 2010; 21:779–785. DOI: 10.1097/EDE.0b013e3181f20bed [PubMed: 20805751]
125. Philippat C, et al. Analgesics During Pregnancy and Undescended Testis. *Epidemiology*. 2011; 22:747–749. DOI: 10.1097/EDE.0b013e318225bf33 [PubMed: 21811116]
126. Rebordosa C, et al. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. *American Journal of Obstetrics and Gynecology*. 2008; 198:178.e171–178.e177. DOI: 10.1016/j.ajog.2007.08.040 [PubMed: 18226618]
127. Møbjerg Kristensen D, Main KM, Jensen TK, Skakkebak NE, Toppari J. Reply: Analgesic use and its effect on male reproduction. *Human Reproduction*. 2011; 26:2259–2260. DOI: 10.1093/humrep/der152 [PubMed: 21602324]
128. Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. *BMC Cancer*. 2015; 15:1–10. [PubMed: 25971837]
129. Lacson JCA, et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. *Cancer*. 2012; 118:5374–5383. [PubMed: 22965656]
130. Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ cell tumors. *Cancer*. 2011; 117:848–853. DOI: 10.1002/cncr.25499 [PubMed: 20925043]
131. Daling JR, et al. Association of marijuana use and the incidence of testicular germ cell tumors. *Cancer*. 2009; 115:1215–1223. DOI: 10.1002/cncr.24159 [PubMed: 19204904]
132. Shono T, Shima Y, Kondo T, Suita S. In utero exposure to mono-N-butyl phthalate impairs insulin-like factor 3 gene expression and the transabdominal phase of testicular descent in fetal rats. *Journal of Pediatric Surgery*. 2005; 40:1861–1864. DOI: 10.1016/j.jpedsurg.2005.08.027 [PubMed: 16338306]
133. Shono T, Suita S, Kai H, Yamaguchi Y. The Effect of a Prenatal Androgen Disruptor, Vinclozolin, on Gubernacular Migration and Testicular Descent in Rats. *Journal of Pediatric Surgery*. 2004; 39:213–216. DOI: 10.1016/j.jpedsurg.2003.10.015 [PubMed: 14966743]

134. Saillenfait AM, Gallissot F, Sabaté JP. Differential developmental toxicities of di-n-hexyl phthalate and dicyclohexyl phthalate administered orally to rats. *Journal of Applied Toxicology*. 2009; 29:510–521. DOI: 10.1002/jat.1436 [PubMed: 19391110]
135. Drake AJ, et al. Glucocorticoids amplify dibutyl phthalate-induced disruption of testosterone production and male reproductive development. *Endocrinology*. 2009; 150:5055–5064. DOI: 10.1210/en.2009-0700 [PubMed: 19819957]
136. Gray LE Jr, et al. Effects of environmental antiandrogens on reproductive development in experimental animals. *Human Reproduction Update*. 2001; 7:248–264. DOI: 10.1093/humupd/7.3.248 [PubMed: 11392371]
137. McKinnell C, et al. Expression of insulin-like factor 3 protein in the rat testis during fetal and postnatal development and in relation to cryptorchidism induced by in utero exposure to Di (n-butyl) phthalate. *Endocrinology*. 2005; 146:4536–4544. DOI: 10.1210/en.2005-0676 [PubMed: 16037377]
138. Jørgensen KT, et al. Risk of cryptorchidism among sons of horticultural workers and farmers in Denmark. *Scandinavian Journal of Work, Environment and Health*. 2014; 40:323–330. DOI: 10.5271/sjweh.3399
139. Weidner IS, Møller H, Jensen TK, Skakkebak NE. Cryptorchidism and hypospadias in sons of gardeners and farmers. *Environmental Health Perspectives*. 1998; 106:793–796. [PubMed: 9831539]
140. Gabel P, et al. The risk of cryptorchidism among sons of women working in horticulture in Denmark: A cohort study. *Environmental Health: A Global Access Science Source*. 2011; 10
141. Kristensen P, Irgens LM, Andersen A, Bye AS, Sundheim L. Birth defects among offspring of Norwegian farmers, 1967–1991. *Epidemiology*. 1997; 8:537–544. DOI: 10.1097/00001648-199709000-00011 [PubMed: 9270956]
142. Morales-Surez-Varela MM, et al. Parental occupational exposure to endocrine disrupting chemicals and male genital malformations: A study in the danish national birth cohort study. *Environmental Health: A Global Access Science Source*. 2011; 10
143. Vaktskjold A, et al. Genital malformations in newborns of female nickel-refinery workers. *Scandinavian Journal of Work, Environment and Health*. 2006; 32:41–50.
144. Jørgensen KT, et al. Risk of cryptorchidism and hypospadias among boys of maternal hairdressers - A Danish population-based cohort study. *Scandinavian Journal of Work, Environment and Health*. 2013; 39:302–309. DOI: 10.5271/sjweh.3330
145. Carran M, Shaw IC. New Zealand Malayan war veterans' exposure to dibutylphthalate is associated with an increased incidence of cryptorchidism, hypospadias and breast cancer in their children. *New Zealand Medical Journal*. 2012; 125:52–63.
146. Bornman R, de Jager C, Worku Z, Farias P, Reif S. DDT and urogenital malformations in newborn boys in a malarial area. *BJU international*. 2010; 106:405–411. DOI: 10.1111/j.1464-410X.2009.09003.x [PubMed: 19849691]
147. Carbone P, et al. Cryptorchidism and hypospadias in the Sicilian district of Ragusa and the use of pesticides. *Reproductive Toxicology*. 2006; 22:8–12. DOI: 10.1016/j.reprotox.2006.01.006 [PubMed: 16530380]
148. García-Rodríguez J, et al. Exposure to pesticides and cryptorchidism: Geographical evidence of a possible association. *Environmental Health Perspectives*. 1996; 104:1090–1095. [PubMed: 8930551]
149. Agopian AJ, Lupo PJ, Canfield MA, Langlois PH. Case-Control Study of Maternal Residential Atrazine Exposure and Male Genital Malformations. *American Journal of Medical Genetics, Part A*. 2013; 161:977–982. DOI: 10.1002/ajmg.a.35815
150. Czeizel AE, Hegedüs S, Tímár L. Congenital abnormalities and indicators of germinal mutations in the vicinity of an acrylonitrile producing factory. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*. 1999; 427:105–123. DOI: 10.1016/S0027-5107(99)00090-1 [PubMed: 10393265]
151. Chul Kim S, Kyoung Kwon S, Pyo Hong Y. Trends in the incidence of cryptorchidism and hypospadias of registry-based data in Korea: A comparison between industrialized areas of

- petrochemical estates and a non-industrialized area. *Asian Journal of Andrology*. 2011; 13:715–718. DOI: 10.1038/aja.2010.53 [PubMed: 20729869]
152. Waliszewski SM, et al. Persistent organochlorine pesticides levels in blood serum lipids in women bearing babies with undescended testis. *Bulletin of Environmental Contamination and Toxicology*. 2005; 75:952–959. DOI: 10.1007/s00128-005-0842-5 [PubMed: 16400584]
153. Trabert B, Longnecker MP, Brock JW, Klebanoff MA, McGlynn KA. Maternal pregnancy levels of trans-nonachlor and oxychlorodane and prevalence of cryptorchidism and hypospadias in boys. *Environmental Health Perspectives*. 2012; 120:478–482. DOI: 10.1289/ehp.1103936 [PubMed: 21975279]
154. Small CM, et al. Maternal exposure to a brominated flame retardant and genitourinary conditions in male offspring. *Environmental Health Perspectives*. 2009; 117:1175–1179. DOI: 10.1289/ehp.0800058 [PubMed: 19654930]
155. Bhatia R, et al. Organochlorine pesticides and male genital anomalies in the child health and development studies. *Environmental Health Perspectives*. 2005; 113:220–224. DOI: 10.1289/ehp.7382 [PubMed: 15687061]
156. Pierik FH, Klebanoff MA, Brock JW, Longnecker MP. Maternal pregnancy serum level of heptachlor epoxide, hexachlorobenzene, and  $\beta$ -hexachlorocyclohexane and risk of cryptorchidism in offspring. *Environmental Research*. 2007; 105:364–369. DOI: 10.1016/j.envres.2007.04.005 [PubMed: 17532317]
157. McGlynn KA, et al. Maternal pregnancy levels of polychlorinated biphenyls and risk of hypospadias and cryptorchidism in male offspring. *Environmental Health Perspectives*. 2009; 117:1472–1476. DOI: 10.1289/ehp.0800389 [PubMed: 19750116]
158. Longnecker MP, et al. Maternal serum level of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene and risk of cryptorchidism, hypospadias, and polythelia among male offspring. *American Journal of Epidemiology*. 2002; 155:313–322. DOI: 10.1093/aje/155.4.313 [PubMed: 11836195]
159. Main KM, et al. Flame retardants in placenta and breast milk and cryptorchidism in newborn boys. *Environmental Health Perspectives*. 2007; 115:1519–1526. DOI: 10.1289/ehp.9924 [PubMed: 17938745]
160. Virtanen HE, et al. Associations between congenital cryptorchidism in newborn boys and levels of dioxins and PCBs in placenta. *International Journal of Andrology*. 2012; 35:283–293. DOI: 10.1111/j.1365-2605.2011.01233.x [PubMed: 22150420]
161. Shen H, et al. Infant exposure to persistent organochlorine compounds is higher in Denmark than in Finland. *WIT Transactions on Ecology and the Environment*. 2008; 110:45–52. DOI: 10.2495/ETOX080051
162. Shen H, et al. Concentrations of persistent organochlorine compounds in human milk and placenta are higher in Denmark than in Finland. *Human reproduction (Oxford, England)*. 2008; 23:201–210. DOI: 10.1093/humrep/dem199
163. Main KM, et al. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environmental Health Perspectives*. 2006; 114:270–276. DOI: 10.1289/ehp.8075 [PubMed: 16451866]
164. Krysiak-Baltyn K, et al. Association between chemical pattern in breast milk and congenital cryptorchidism: Modelling of complex human exposures. *International Journal of Andrology*. 2012; 35:294–302. DOI: 10.1111/j.1365-2605.2012.01268.x [PubMed: 22519522]
165. Damgaard IN, et al. Persistent pesticides in human breast milk and cryptorchidism. *Environmental Health Perspectives*. 2006; 114:1133–1138. DOI: 10.1289/ehp.8741 [PubMed: 16835070]
166. Brucker-Davis F, et al. Cord blood thyroid tests in boys born with and without cryptorchidism: Correlations with birth parameters and in utero xenobiotics exposure. *Thyroid*. 2011; 21:1133–1141. DOI: 10.1089/thy.2010.0459 [PubMed: 21875366]
167. Arrebola JP, et al. A novel biomarker for anti-androgenic activity in placenta reveals risks of urogenital malformations. *Reproduction*. 2015; 149:605–613. DOI: 10.1530/REP-14-0525 [PubMed: 25784770]

168. Jensen DV, et al. No association between exposure to perfluorinated compounds and congenital cryptorchidism: A nested case-control study Among 215 Boys from Denmark and Finland. *Reproduction*. 2014; 147:411–417. DOI: 10.1530/REP-13-0444 [PubMed: 24218628]
169. Rantakokko P, et al. Association of placenta organotin concentrations with congenital cryptorchidism and reproductive hormone levels in 280 newborn boys from Denmark and Finland. *Human Reproduction*. 2013; 28:1647–1660. DOI: 10.1093/humrep/det040 [PubMed: 23520400]
170. Fernandez MF, et al. Human exposure to endocrine-disrupting chemicals and prenatal risk factors for cryptorchidism and hypospadias: A nested case-control study. *Environmental Health Perspectives*. 2007; 115:8–14. DOI: 10.1289/ehp.9351 [PubMed: 18174944]
171. Fernández MF, et al. Bisphenol A and other phenols in human placenta from children with cryptorchidism or hypospadias. *Reproductive Toxicology*. 2016; 59:89–95. DOI: 10.1016/j.reprotox.2015.11.002 [PubMed: 26602963]
172. Fénelichel P, et al. Unconjugated bisphenol A cord blood levels in boys with descended or undescended testes. *Human Reproduction*. 2012; 27:983–990. DOI: 10.1093/humrep/der451 [PubMed: 22267833]
173. Koskenniemi JJ, et al. Association between levels of persistent organic pollutants in adipose tissue and cryptorchidism in early childhood: a case-control study. *Environmental Health: A Global Access Science Source*. 2015; 14
174. Hosie S, Loff S, Witt K, Niessen K, Waag KL. Is there a correlation between organochlorine compounds and undescended testes? *European Journal of Pediatric Surgery*. 2000; 10:304–309. [PubMed: 11194541]
175. Saiyed H, et al. Effect of endosulfan on male reproductive development. *Environmental Health Perspectives*. 2003; 111:1958–1962. [PubMed: 14644673]
176. Komarowska MD, et al. Serum Bisphenol A Level in Boys with Cryptorchidism: A Step to Male Infertility? *International Journal of Endocrinology*. 2015; 2015
177. Brucker-Davis F, et al. Cryptorchidism at birth in Nice area (France) is associated with higher prenatal exposure to PCBs and DDE, as assessed by colostrum concentrations. *Human Reproduction*. 2008; 23:1708–1718. DOI: 10.1093/humrep/den186 [PubMed: 18503055]
178. Chevrier C, et al. Maternal urinary phthalates and phenols and male genital anomalies. *Epidemiology*. 2012; 23:353–356. DOI: 10.1097/EDE.0b013e318246073e [PubMed: 22317818]
179. Jackson MB, Swerdlow AJ. Seasonal variations in cryptorchidism. *Journal of Epidemiology and Community Health*. 1986; 40:210–213. [PubMed: 2877045]
180. Kaleva M, et al. Circannual rhythm in the incidence of cryptorchidism in Finland. *International Journal of Andrology*. 2005; 28:53–57. DOI: 10.1111/j.1365-2605.2005.00510.x
181. Mamoulakis C, et al. Cryptorchidism: Seasonal variations in Greece do not support the theory of light. *Andrologia*. 2002; 34:194–203. DOI: 10.1046/j.1439-0272.2002.00492.x [PubMed: 12059817]
182. Brantsæter AL, et al. Organic food consumption during pregnancy and hypospadias and cryptorchidism at birth: The Norwegian mother and child cohort study (MoBa). *Environmental Health Perspectives*. 2016; 124:357–364. DOI: 10.1289/ehp.1409518 [PubMed: 26307850]
183. Fulgoni VL 3rd, Keast DR, Lieberman HR. Trends in intake and sources of caffeine in the diets of US adults: 2001–2010. *The American journal of clinical nutrition*. 2015; 101:1081–1087. DOI: 10.3945/ajcn.113.080077 [PubMed: 25832334]
184. Ralis ZA. Birth trauma to muscles in babies born by breech delivery and its possible fatal consequences. *Arch Dis Child*. 1975; 50:4–13. [PubMed: 1124942]
185. Dunn PM. Testicular birth trauma. *Arch Dis Child*. 1975; 50:744–745.
186. Tiwary CM. Testicular damage following breech delivery. *Clin Res*. 1973; 21
187. Depue RH. Maternal and gestational factors affecting the risk of cryptorchidism and inguinal hernia. *International Journal of Epidemiology*. 1984; 13:311–318. [PubMed: 6149198]
188. Depue RH. Cryptorchidism, and epidemiologic study with emphasis on the relationship to central nervous system dysfunction. *Teratology*. 1988; 37:301–305. [PubMed: 2899361]

189. Gurney J, Sarfati D, Stanley J, Studd R. Do ethnic patterns in cryptorchidism reflect those found in testicular cancer? *Journal of Urology*. 2013; 190:1852–1857. DOI: 10.1016/j.juro.2013.05.002 [PubMed: 23665269]
190. Jain VG, Singal AK. Shorter anogenital distance correlates with undescended testis: A detailed genital anthropometric analysis in human newborns. *Human Reproduction*. 2013; 28:2343–2349. DOI: 10.1093/humrep/det286 [PubMed: 23838161]
191. Kramer MS. Determinants of low birth weight: Methodological assessment and meta-analysis. *Bulletin of the World Health Organization*. 1987; 65:663–737. [PubMed: 3322602]
192. Kayode GA, et al. Contextual risk factors for low birth weight: A multilevel analysis. *PLoS ONE*. 2014; 9
193. Jensen MS, et al. Cryptorchidism concordance in monozygotic and dizygotic twin brothers, full brothers, and half-brothers. *Fertility and Sterility*. 2010; 93:124–129. DOI: 10.1016/j.fertnstert.2008.09.041 [PubMed: 19022430]
194. Schnack TH, et al. Familial aggregation of cryptorchidism--a nationwide cohort study. *American journal of epidemiology*. 2008; 167:1453–1457. [PubMed: 18436537]
195. Nef S, Parada LF. Cryptorchidism in mice mutant for *Insl3*. *Nature Genetics*. 1999; 22:295–299. DOI: 10.1038/10364 [PubMed: 10391220]
196. Elert A, Jahn K, Heidenreich A, Hofmann R. Population-based investigation of familial undescended testis and its association with other urogenital anomalies. *Journal of Pediatric Urology*. 2005; 1:403–407. DOI: 10.1016/j.jpuro.2005.04.005 [PubMed: 18947580]
197. Barthold JS, et al. Pathway analysis supports association of nonsyndromic cryptorchidism with genetic loci linked to cytoskeleton-dependent functions. *Human Reproduction*. 2015; 30:2439–2451. DOI: 10.1093/humrep/dev180 [PubMed: 26209787]
198. El Houate B, et al. Novel mutations involving the *INSL3* gene associated with cryptorchidism. *J Urol*. 2007; 177:1947–1951. DOI: 10.1016/j.juro.2007.01.002 [PubMed: 17437853]
199. Ferlin A, et al. Mutations in *INSL3* and *RXFP2* genes in cryptorchid boys. *Annals of the New York Academy of Sciences*. 2009; 1160:213–214. DOI: 10.1111/j.1749-6632.2008.03784.x [PubMed: 19416190]
200. Ferlin A, et al. Mutational screening of *NR5A1* gene encoding steroidogenic factor 1 in cryptorchidism and male factor infertility and functional analysis of seven undescribed mutations. *Fertility and Sterility*. 2015; 104:163–169.e161. DOI: 10.1016/j.fertnstert.2015.04.017 [PubMed: 25989977]
201. Qin XY, et al. Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias. *Journal of Human Genetics*. 2012; 57:434–441. DOI: 10.1038/jhg.2012.48 [PubMed: 22648180]
202. Gurney J, Sarfati D, Stanley J. Obscure etiology, unusual disparity: the epidemiology of testicular cancer in New Zealand. *Cancer Causes and Control*. 2015; 26:561–569. [PubMed: 25687480]
203. Sarfati D, Shaw C, Blakely T, Atkinson J, Stanley J. Ethnic and socioeconomic trends in testicular cancer. *International Journal of Cancer*. 2010; 128:1683–1691. [PubMed: 20518014]
204. Bay K, Main KM, Toppari J, Skakkebaek NE. Testicular descent: *INSL3*, testosterone, genes and the intrauterine milieu. *Nature Reviews Urology*. 2011; 8:187–196. [PubMed: 21403659]
205. Zimmermann S, et al. Targeted disruption of the *Insl3* gene causes bilateral cryptorchidism. *Molecular Endocrinology*. 1999; 13:681–691. [PubMed: 10319319]
206. Hutson JM, Balic A, Nation T, Southwell B. Cryptorchidism. *Seminars in pediatric surgery*. 2010; 19:215–224. DOI: 10.1053/j.sempedsurg.2010.04.001 [PubMed: 20610195]
207. Hughes IA, Acerini CL. Factors controlling testis descent. *European Journal of Endocrinology*. 2008; 159:S75–S82. DOI: 10.1530/EJE-08-0458 [PubMed: 18647820]
208. Virtanen HE, et al. Mild gestational diabetes as a risk factor for congenital cryptorchidism. *Journal of Clinical Endocrinology and Metabolism*. 2006; 91:4862–4865. DOI: 10.1210/jc.2006-1420 [PubMed: 17032715]
209. Nielsen GL, et al. Risk of specific congenital abnormalities in offspring of women with diabetes. *Diabetic Medicine*. 2005; 22:693–696. DOI: 10.1111/j.1464-5491.2005.01477.x [PubMed: 15910618]

210. Bánhidly F, Ács N, Puhó EH, Czeizel AE. Congenital abnormalities in the offspring of pregnant women with type 1, type 2 and gestational diabetes mellitus: A population-based case-control study. *Congenital Anomalies*. 2010; 50:115–121. DOI: 10.1111/j.1741-4520.2010.00275.x [PubMed: 20184644]
211. Trabert B, et al. Gestational diabetes and the risk of cryptorchidism and hypospadias. *Epidemiology*. 2014; 25:152–153. DOI: 10.1097/EDE.000000000000014 [PubMed: 24296929]
212. Agopian AJ, Langlois PH, Ramakrishnan A, Canfield MA. Epidemiologic features of male genital malformations and subtypes in Texas. *American journal of medical genetics. Part A*. 2014; 164a:943–949. DOI: 10.1002/ajmg.a.36389 [PubMed: 24458943]
213. Klebanoff MA, Mills JL. Is vomiting during pregnancy teratogenic? *British Medical Journal*. 1986; 292:724–726. [PubMed: 3082411]
214. Czeizel AE, Puhó E, Ács N, Bánhidly F. Inverse association between severe nausea and vomiting in pregnancy and some congenital abnormalities. *American Journal of Medical Genetics*. 2006; 140 A:453–462. DOI: 10.1002/ajmg.a.31097 [PubMed: 16470733]
215. Zhang J, Olshan A, Cai WW. Birth defects in relation to threatened abortion. *Epidemiology*. 1994; 5:341–344. [PubMed: 8038250]
216. Zhang J, Cai WW. Association of the common cold in the first trimester of pregnancy with birth defects. *Pediatrics*. 1993; 92:559–563. [PubMed: 8414827]
217. Ingstrup KG, et al. Maternal bereavement and cryptorchidism in offspring. *Epidemiology (Cambridge, Mass)*. 2015; 26:100–105. DOI: 10.1097/EDE.0000000000000194
218. Shono T, Suita S. Disturbed pituitary-testicular axis inhibits testicular descent in the prenatal rat. *BJU international*. 2003; 92:641–643. DOI: 10.1046/j.1464-410X.2003.04436.x [PubMed: 14511052]
219. Adams SV, Hastert TA, Huang Y, Starr JR. No Association between Maternal Pre-pregnancy Obesity and Risk of Hypospadias or Cryptorchidism in Male Newborns. *Birth defects research. Part A, Clinical and molecular teratology*. 2011; 91:241–248. DOI: 10.1002/bdra.20805 [PubMed: 21462299]
220. Aschim EL, et al. Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. *Journal of Clinical Endocrinology and Metabolism*. 2004; 89:5105–5109. DOI: 10.1210/jc.2004-0293 [PubMed: 15472213]
221. Zhou B, et al. The variations in the AXIN1 gene and susceptibility to cryptorchidism. *Journal of Pediatric Urology*. 2015; 11:132.e131–132.e135. DOI: 10.1016/j.jpuro.2015.02.007 [PubMed: 25802106]
222. Tang KF, Zheng JZ, Xing JP. Molecular analysis of SNP12 in estrogen receptor  $\alpha$ . Gene in hypospadiac or cryptorchid patients from northwestern China. *Urologia Internationalis*. 2011; 87:359–362. DOI: 10.1159/000330902 [PubMed: 21934279]
223. Yoshida R, et al. Association of cryptorchidism with a specific haplotype of the estrogen receptor  $\alpha$  gene: Implication for the susceptibility to estrogenic environmental endocrine disruptors. *Journal of Clinical Endocrinology and Metabolism*. 2005; 90:4716–4721. DOI: 10.1210/jc.2005-0211 [PubMed: 15899960]
224. Galan JJ, et al. Molecular analysis of estrogen receptor alpha gene AGATA haplotype and SNP12 in European populations: Potential protective effect for cryptorchidism and lack of association with male infertility. *Human Reproduction*. 2007; 22:444–449. DOI: 10.1093/humrep/del391 [PubMed: 17099213]
225. Kolon TF, et al. Analysis of homeobox gene HOXA10 mutations in cryptorchidism. *Journal of Urology*. 1999; 161:275–280. DOI: 10.1016/S0022-5347(01)62132-3 [PubMed: 10037424]
226. Foresta C, Ferlin A. Role of INSL3 and LGR8 in cryptorchidism and testicular functions. *Reproductive biomedicine online*. 2004; 9:294–298. [PubMed: 15353080]
227. Gorlov IP, et al. Mutations of the GREAT gene cause cryptorchidism. *Human Molecular Genetics*. 2002; 11:2309–2318. [PubMed: 12217959]
228. Salemi M, et al. Expression of Phosphodiesterase 4B cAMP-Specific Gene in Subjects With Cryptorchidism and Down's Syndrome. *Journal of Clinical Laboratory Analysis*. 2015


229. Ars E, et al. Further insights into the role of t222p variant of rxfp2 in non-syndromic cryptorchidism in two mediterranean populations. *International Journal of Andrology*. 2011; 34:333–338. DOI: 10.1111/j.1365-2605.2010.01088.x [PubMed: 20636340]
230. Wada Y, Okada M, Fukami M, Sasagawa I, Ogata T. Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1. *Fertility and Sterility*. 2006; 85:787–790. DOI: 10.1016/j.fertnstert.2005.09.016 [PubMed: 16500365]
231. Salemi M, et al. SPAG5 mRNA is over-expressed in peripheral blood leukocytes of patients with Down's syndrome and cryptorchidism. *Neurological Sciences*. 2013; 34:549–551. DOI: 10.1007/s10072-012-1152-4 [PubMed: 22773063]
232. Salemi M, et al. Expression of STRBP mRNA in patients with cryptorchidism and Down's syndrome. *Journal of Endocrinological Investigation*. 2012; 35:5–7. [PubMed: 22391137]
233. Chew G, Hutson JM. Incidence of cryptorchidism and ascending testes in Trisomy 21: A 10 year retrospective review. *Pediatric Surgery International*. 2004; 20:744–747. DOI: 10.1007/s00383-004-1290-8 [PubMed: 15517292]
234. Barthold JS, et al. Altered infant feeding patterns in boys with acquired nonsyndromic cryptorchidism. *Birth Defects Research Part A - Clinical and Molecular Teratology*. 2012; 94:900–907. DOI: 10.1002/bdra.23075 [PubMed: 23081935]

### Review Criteria

We conducted searches of the Scopus database using the following search terms: ((cryptorchidism) OR (cryptorchism) OR (undescended test\*)) AND ((exposure\*) OR (exposed) OR (risk) OR (risk factor\*)) AND ((epidemiology) OR (case-control) OR (cohort) OR (association) OR (associated) OR (population)). In addition, we scanned the reference lists of relevant articles to identify additional papers. The final search was conducted on 8<sup>th</sup> June 2016.

### Key Points

- Cryptorchidism is one of the most common congenital abnormalities found among males, and is one of the few known risk factors for testicular cancer (TC).
- Like testicular cancer, the key exposures in the occurrence of cryptorchidism (undescended testes) remain elusive.
- Despite a considerable body of aetiological research, there are few exposures for which there is consistent evidence of an association with cryptorchidism.
- In those cases where evidence appears unequivocal, the measured exposure is likely to be a surrogate for the true causal exposure.
- The relative importance of each risk factor may vary considerably between mother/son pairs depending on an array of genetic, maternal, placental and foetal factors – all of which could vary between regions.



**Figure 1. Descent of the testis**

(Modified with permission from Hutson JM, Thorup JM, Beasley SW. Descent of the testis. 2nd ed: Springer, 2016<sup>18</sup>) a) After gestational week 8, the developing testes in males are found lying in an intra-abdominal position. Sometime between the 8<sup>h</sup> and 15<sup>th</sup> week of gestation, the testes begin the first phase of their descent. b) The second phase of testicular descent (the *inguinoscrotal phase*) occurs during 25–35 weeks' gestation. The gubernaculum bulges out from the inguinal region of the abdominal wall and begins to migrate toward the scrotum.<sup>28</sup> c) Around week 35 of gestation, the gubernaculum (with its testis contained inside the *processus vaginalis*) finally comes to rest in the scrotal sack. d) Once the descent is complete, the *processus vaginalis* pouch closes at the top of the scrotum. Also at this time, the gubernaculum adheres to the scrotal wall – anchoring both itself and the contained testis into their terminal position<sup>18</sup> – while the remnants of the *processus vaginalis* above the scrotum regress.